Long title: The Safety of EIDD-2801 and Its  Effect on Viral Shedding of SAR S-CoV-2
Short title: The Safety of EIDD-2801 and Its  Effect on Viral Shedding of SARS- CoV-2
(The END-COVID Study)
Ridgeback Biotherapeutic s Protocol #: EIDD-2801-2004
Clinical Pha
se:2
Study Registry ID: [REMOVED]
IND Sponsor/Principal Investigator:
Sponsor: Ridgeback Biotherapeutics LP
Principal Investigator: Ashwin Balagopal, MD
IND Number: 147734
Study Drug: EIDD-2801 and Placebo Capsules
Version/Date of Issue: Amendment 6, Version 7.0, 18 May 2021
Confidential Information: The information contained in th is document is the property of 
Ridgeback Biotherapeutics LP and may not be repr oduced, published, or disclosed to others 
without written authorization from Ridgeback Biotherapeutics LP.

Protocol EIDD-2801-2004
Ridgeback Biotherapeutics LP Version: 7.0
18 May 2021
Page 4 of 64
PROTOCOL SUMMARY
Sample Size: 84 with allowance to increase up to 15% over as needed for dropou ts or logistics 
considerations.Study Population: Adults aged 18 years or older w ho are hospitalized with a new diagnosis of coronavirus disease-2019 
(COVID-19) with a duration of symptoms Â”7 days. Patients requiring admiss ion to an intensive care unit 
or mechanical ventila tion are not eligible.
Study Duration:Length of study: Approximately 10 m onths from First Participant Fi rst Visit to Last Participant Last Visit
Length of participation of study pa rticipants: Up to 30 days, inc luding a 0 to 2-day screening window, 
5 days of dosing with study drug, and  23 days of post-dosing follow-up.
Locations:
Johns Hopkins Health System, The Un iversity of California, Los A ngeles, and up to 5 additional sites in 
the United States
Study Design: Phase 2a randomized, placebo-controlled, double-blinded clinica l trial of EIDD-2801 (also known as 
MK-4482) in adult men and women who have tested positive for se vere acute respiratory syndrome-
coronavirus-2 (SARS-CoV-2) infec tion by polymerase chain reaction  (PCR) test within 6 days
(144 hours) prior to randomizati on and are hospitalized with a diagn osis of COVID-19. Rapid enrollment 
and treatment will be initiated suc h that the first dose of EIDD-2801 or placebo will be administered as
soon as possible and within 7 days of onset of symptoms.RandomizationParticipants will be enrolled in up to 4 sequential study parts . During Part 1, participants will be 
randomized in a 1:1:1 ratio to: 200 mg EIDD-2801:400 mg EIDD-280 1:placebo.  In Part 2 of the study, 
21 participants will be randomize d in a 2:1 ratio to receive EIDD- 2801 400 mg or placebo and in Part 3 of 
the study, 21 participants will be randomized in a 2:1 ratio to r eceive EIDD-2801 800 mg or placebo.  An 
optional Part 4 may be added duri ng which 21 participants will b e randomized in a 2:1 ratio to EIDD-
2801:placebo and the dose of EIDD- 2801 may be the same or lower than doses studied in previous 
Part(s), but not to exceed 800 mg BID.The study parts will be conducted a s follows:  Enrollment into Part 1 of the study may be terminated upon 
approval and implementation of Protocol Amendment 3, and enroll ment into Part 2 will be initiated 
immediately thereafter.  Enrollment into Part 3 will be initiat ed once Part 2 has been fully enrolled.  If 
initiated, Part 4 may begin enrol ling participants as soon as Pa rt 3 has been fully enrolled. Study Parts 2 
and 3 may be terminated prematurely based on emerging data from  this and other ongoing studies of 
EIDD-2801.
Protocol EIDD-2801-2004
Ridgeback Biotherapeutics LP Version: 7.0
18 May 2021
Page 5 of 64
Study Drug:
Æ”EIDD-2801 and matching placebo
Primary Efficacy Objective: 
To test whether orally admin istered EIDD-2801 results in a great er proportion of clearance from 
nasopharyngeal (NP) swabs compar ed to placebo in hospitalized adu lts by achieving undetectable (below 
the limit of detection [LOD] of the assay) viral RNA by Day 5 after initiation of study drug.
Primary Efficacy Endpoint: 
Achievement of undetectable (below t he LOD of the assay) SARS-CoV-2  RNA by Day 5 in NP swabs by 
quantitative reverse transcription polymerase chain reaction (q PCR). 
Primary Safety Objective:To evaluate the safety of trea tment with EIDD-2801 in participan ts diagnosed with COVID-19
Primary Safety Endpoints:
1. Adverse events (AEs)
2. Serious adverse events (SAEs)3. Physical examinati on including vital signs
4. Safety laboratory assessments
xcomplete blood counts (CBC) with differentials-decrease in hemoglobin ( Hgb) by >1 g/dL, or to <9 g/dL
-decrease in platelet count by 50,000/Î¼L, or to <75,000/Î¼L
xcomprehensive metabolic panels  (CMP) including liver function t ests
-increase in aspartate aminotrans ferase (AST), alanine aminotrans ferase (ALT), amylase, or 
lipase to Â•3x the upper limit of normal (ULN)
xurinalysis
5. Electrocardiograms (ECGs)
Secondary Virologic Objectives: To evaluate the efficacy of EIDD-2801 on clearance of SARS-CoV- 2 RNA.
Secondary Virologic Endpoints:
1. Time to clearance of viral RNA in NP swabs
-by qPCR 
2. The decline in viral RNA  by Day 3, Day 5, Day 8, Day 11, Day 15, Day 19, and Day 28 after 
initiation of study drug in NP swabs
-by qPCR 
Protocol EIDD-2801-2004
Ridgeback Biotherapeutics LP Version: 7.0
18 May 2021
Page 6 of 64
3. Rate of decline in viral RNA (change in log 10 copies/mL per day) in NP swabs
-by qPCR  
Secondary Clinical Objective  
To evaluate the effect of EIDD-2801 on improvement of clinical symptoms and signs of COVID-19.  
Secondary Clinical Endpoints:
1. Peak stage on the World Healt h Organization (WHO) Ordinal Sca le for Clinical Improvement
(Appendix 1)  OR clinical requirement for addition of other an tivirals including but not limited to:
-Pegylated interferon alpha
-Inhaled interferon beta1 
-Ribavirin (any formulation) 
-Any interleukin (IL)-6 inhibitor
2. Number of days of supplemental oxygen  
3. Number of days of mechanical ventilation4. Number of days in the Intensive Care Unit (ICU)5. Death
Exploratory Virologic Objective 
To evaluate the efficacy of EIDD-2801 to clear SARS-CoV-2 RNA a nd infectious virus.  
Exploratory Virologic Endpoints:
1. Achievement of undetectable(below the LOD of the assay) viral titers by Day 5 in NP swabs
-by infectivity assay  
2. Time to clearance of inf ectious virus in NP swabs
-by infectivity assay
3. Clearance of infectious vir us by Day 3 and Day 5 in NP swabs 
-by infectivity assay
4. The number of acquired single- nucleotide polymorphisms in SAR S-CoV-2 genomes by Day 5 or 
Day 11 in NP swabs 
-by viral sequencing 
Exploratory Clinical Objective
To ascertain the role of EIDD- 2801 in improvement of clinical symptoms and signs of COVID-19. 
Exploratory Clin ical Endpoints:  
1. Days of hospitalization
2. Time until on room air without r equirement for supplemental o xygen
3. Time to resolution of COVI D-19 symptoms defined as: 
-Fevers OR 
Protocol EIDD-2801-2004
Ridgeback Biotherapeutics LP Version: 7.0
18 May 2021
Page 7 of 64
-At least one of the IROORZLQJV\PSWRPVFRXJKVKRUWQ HVVRIEUHDWKUHVSLUDWRU\UDWHÂ•
radiographic evidence of pneumonia OR
-other clinical symptoms or si gns of pneumonia that are not otherwise explained by 
comorbidities or co-diagnoses
4. Number of days until a 2-point  decrease in stage according to  the WHO Ordinal Scale for Clinical 
Improvement (Appendix 1) .
5. Radiologic improvement by gradi ng chest diagnostics (when rad iography is available)
6. Change in interleukin (IL)-6 levels by Day 5 
Pharmacokinetic Objectives 
(To be conducted in a subset of pa rticipants at clinical sites t hat can participate, including but not limited 
to  on Days 3 to 4 of dosing):
Secondary:
To evaluate EIDD-1931 pharm acokinetics in plasma.   
Exploratory:
To characterize the pharmacokinetics of EIDD-2061 (NHC-TP) in peripheral blood mononuclear cells 
(PBMC) in a subset of participants. 
Pharmacokinetic Endpoints: 
Secondary (plasma analysis):
1. Maximum EIDD-1931 concentration (C max) 
2. 1.5-hour EIDD-1931 concentration (C 1.5) 
3. 3-hour EIDD-1931 concentration (C 3) 
4. Area under the concentration:  time curve of EIDD-1931 (AUC) 
5. Elimination half-life (t 1/2) of EIDD-1931 
Exploratory (PBMC analysis):
1. Maximum EIDD-2061 concentration (C max) 
2. EIDD-2061 time of maximal concentration (t max) 
3. Elimination half-life of EIDD-2061 (t 1/2) 
4. Area under the concentrati on: time curve of EIDD-2061 (AUC 0-12)  
5. Parent: metabolite (EIDD-1931: EIDD-2061) concentration ratio at each time point, in which both 
plasma and PBMC are processed for PK analysis

Protocol EIDD-2801-2004
Ridgeback Biotherapeutics LP Version: 7.0
18 May 2021
Page 8 of 64
TABLE OF CONTENTS
SPONSOR APPROVAL................................................................................................................. 2  
SIGNATURE PAGE................................................. ...................................................................... 3  
PROTOCOL SUMMARY............................................... ............................................................... 4  
TABLE OF CONTENTS.............................................. .................................................................. 8  
LIST OF APPENDICES ............................................................................................................... 11  
LIST OF FIGURES ............................................... ....................................................................... 11  
LIST OF ABBREVIATIONS ......................................... .............................................................. 12  
1. STUDY OBJECTIVES ......................................................................................................... 14  
1.1. Primary Efficacy Objective ............................................................................................ 14  
1.2. Primary Safety Objective ............................................................................................... 14  
1.3. Secondary Virologic Objective ................................. ..................................................... 14  
1.4. Secondary Clinical Objectives ....................................................................................... 15  
1.5. Exploratory Virologic Objective ............................... ..................................................... 15  
1.6. Exploratory Clinical Objective ....................................................................................... 16  
1.7. Pharmacokinetic Objectives ........................................................................................... 16  
2. BACKGROUND AND SCIENTIFIC RATIONALE ........................... ................................ 18  
2.1. Abstract .......................................................................................................................... 18  
2.2. Background .................................................................................................................... 19  
2.3. Known Potential Risks ......................................... .......................................................... 20  
2.3.1.  Clinical Findings ...................................................................................................... 20  
2.3.2.  Nonclinical Findings ................................................................................................ 21  
2.3.3.   ....................... ...................................... 25 
2.4. Known Potential Benefits ............................................................................................... 26  
2.4.1.  Potential Benefits of Treatment ............................................................................... 26  
2.4.2.  Potential Benefits of Clinical  Monitoring and Virologic Testing  ............................ 27  
3. PATIENT POPULATION ............................................ ......................................................... 28  
3.1. Inclusion Criteria for Enrollment ................................................................................... 28  
3.2. Exclusion Criteria for Enrollment .................................................................................. 29  
4. INVESTIGATIONAL PLAN ................................................................................................ 32  
4.1. Definitions ...................................................................................................................... 32  
4.2. Randomization and Blinding .......................................................................................... 32  
4.3. Intervention..................................................................................................................... 33  
4.3.1.  Screening ..................................................... ............................................................. 33  

Protocol EIDD-2801-2004
Ridgeback Biotherapeutics LP Version: 7.0
18 May 2021
Page 9 of 64
4.3.2.  Administration of Study Drugs ................................................................................ 33  
4.3.3.  Virologic Assessments ............................................................................................. 33  
4.3.4.  Clinical Assessments ................................................................................................ 34  
4.4. Pregnancy Testing .......................................................................................................... 34  
4.5. Serology .......................................................................................................................... 35  
4.6. Rationale for Medication Dosing ................................................................................... 35  
4.7. Concomitant Medications ....................................... ........................................................ 35  
4.8. Study Discontinuation ......................................... ........................................................... 35  
5. PHARMACEUTICAL INFORMATION .................................... ......................................... 37  
5.1. Agent Accountability ..................................................................................................... 37  
5.2. Mode of Action .............................................................................................................. 37  
5.3. Description ................................................... .................................................................. 38  
5.4. Packaging ..................................................... .................................................................. 38  
5.5. Storage ....................................................... ..................................................................... 38  
5.6. Route of Administration ................................................................................................. 38  
5.7. Participant Care  Implications ......................................................................................... 38  
5.8. Returns and Reconciliations ........................................................................................... 38  
5.9. Pharmacokinetics .............................................. .............................................................. 39  
6. STATISTICAL CONSIDERATIONS .................................... .............................................. 40  
6.1. Sample Size and Power Considerations ......................................................................... 40  
6.2. Statistical Analysis .......................................... ............................................................... 40  
6.2.1.  Analysis Populations ................................................................................................ 40  
6.2.2.  Data Handling .......................................................................................................... 41  
6.2.3.  Handling of Dropouts, Missing Data, and Outliers............... ................................... 41  
6.2.4.  Analysis of Primary Endpoint .................................................................................. 41  
6.2.5.  Analysis of Secondary Endpoints ............................................................................ 42  
6.2.6.  Analysis of Adverse Event Data ................................ .............................................. 42  
6.2.7.  Analysis of Other Safety and Clinical Data .................... ......................................... 42  
6.2.8.  Analysis of Pharmacokinetic Data ............................... ............................................ 43  
7. STUDY PROCEDURES .............................................. ......................................................... 44  
7.1. Schedule of Events ............................................ ............................................................. 44  
8. ADVERSE EVENTS, RISKS, AND BENEFITS ........................... ...................................... 49  
8.1. Potential Benefits of treatment ....................................................................................... 49  
8.2. Potential benefits of clinical monitoring ..................... ................................................... 49  
Protocol EIDD-2801-2004
Ridgeback Biotherapeutics LP Version: 7.0
18 May 2021
Page 10 of 64
8.3. Potential risks ................................................................................................................. 49  
8.4. Alternatives..................................................................................................................... 49  
8.5. Definitions ...................................................................................................................... 49  
8.5.1.  Adverse Event .......................................................................................................... 49  
8.5.2.  Serious Adverse Event ......................................... .................................................... 50  
8.6. Relationship .................................................. .................................................................. 51  
8.7. Assessment of Grade/Severity .................................. ...................................................... 52  
8.8. Expectedness .................................................................................................................. 52  
8.9. Handling of Expedited Safety Reports .......................... ................................................. 52  
8.10.  Reporting ..................................................... ................................................................... 52  
8.10.1.  Routine Adverse Event Reporting ............................... ............................................ 53  
8.10.2.  Laboratory Test Abnormalities ................................................................................ 53  
8.10.3.  Serious Adverse Event Reporting ............................... ............................................. 53  
8.10.4.  Pregnancy and Exposure During Breastfeeding ...................................................... 55  
9. SAFETY OVERSIGHT ......................................................................................................... 56  
9.1. Monitoring Plan .............................................................................................................. 56  
9.2. Stopping Criteria for the Study....................................................................................... 56  
10. ETHICS/PROTECTION OF HUMAN SUBJECTS ......................................................... 58  
10.1.  Ethical Standard.............................................................................................................. 58  
10.2.  Institutional Review Board .................................... ......................................................... 58  
10.3.  Informed Consent Process .............................................................................................. 58  
10.4.  Participant Confidentiality.............................................................................................. 59  
10.5.  Future Use of Stored Specimens .................................................................................... 59  
10.6.  Data Management and Monitoring ................................................................................. 59  
10.6.1.  Source Documents ................................................................................................... 59  
10.6.2.  Data Management Plan .......................................... .................................................. 60  
10.6.3.  Data Capture Methods ............................................................................................. 60  
10.6.4.  Study Record Retention ........................................ ................................................... 60  
11. REFERENCES .................................................... ............................................................... 61  
Protocol EIDD-2801-2004
Ridgeback Biotherapeutics LP Version: 7.0
18 May 2021
Page 11 of 64
LIST OF APPENDICES
Appendix 1.  World Health Organization Ordinal Scale for Clinical Improvement o f COVID-19 
Disease ....................................................... ........................................................................ 62  
Appendix 2.  Contraceptive Guidance ..................................................................................................... 63  
LIST OF FIGURESFigure 1.
  23 

Protocol EIDD-2801-2004
Ridgeback Biotherapeutics LP Version: 7.0
18 May 2021
Page 12 of 64
LIST OF ABBREVIATIONS
ADR: Adverse Drug Reaction
AE: Adverse Event/Adverse ExperienceALT: Alanine aminotransferase
ARDS: Acute Respiratory Distress Syndrome
AST: Aspartate aminotransferase
AUC: Area under the curve
AUC
0-12: Area under the concentration-time curve throughout 12-hour dosing interval
AUC 0-24: Area under the concentration- time curve throughout 24-hour do sing interval
AUC 0-8: Area under the concentratio n-time curve throughout 8-hour dosing interval
BID: Bis in die, or twice dailyBiPAP: Bilevel positive airway pressure
BMI: Body mass index, or weight i n kilograms divided by height in meters squared
C
1.5: One point five-hour concentration
C3: Three-hour concentration
CDC: United States Centers for Disease Control and Prevention
CFR: Code of Federal Regulations
CHKV: Chikungunya virus
CLIA: Clinical Laboratory Imp rovement Amendment of 1988
Cmax: Maximum concentration
COI: Conflict of Interest
CoV: Coronavirus
COVID-19: Coronavirus Disease 
CRF: Case Report FormCRS: Cytokine Release SyndromeDMC: Data Management CenterDRF: Dose range finding
ECG: Electrocardiogram
EEEV: Eastern equine encephalitis virus
EUA: Emergency Use Authorization
FDA: Food and Drug AdministrationGCP: Good Clinical PracticeHBV: Hepatitis B virus
HCV: Hepatitis C virus
HIV: Human immunodeficiency virus
IB: Investigatorâ€™s Brochure
I/E: Inclusion and exclusion
ICF: Informed Consent (Informed Consent Form)
ICU: Intensive Care UnitIEC: Independent ethics committeeIRB: Institutional review board

Protocol EIDD-2801-2004
Ridgeback Biotherapeutics LP Version: 7.0
18 May 2021
Page 13 of 64
IWRS: Interactive web response system
LOD: Limit of detection
MAD: Multiple ascending dose
MERS: Middle East Respiratory Syndrome 
MERS-CoV: Middle East Respiratory Syndrome CoronavirusMTD: Maximum tolerated dose
NOAEL: No observed adverse effect level
NP: Nasopharyngeal
PFA: Plaque forming assay
PO2: Partial pressure of oxygen
QD: Quaque die, or once daily
QOD: Quaque altera die, or once every other day
qPCR: Quantitative pol ymerase chain reaction
RSV: Respiratory syncytial virusRT-PCR: Reverse transcriptase  polymerase chain reaction
SAD: Single ascending dose
SAE: Serious adverse event
SARS: Severe Acute Respiratory SyndromeSARS-CoV: Severe Acute Resp iratory Syndrome Coronavirus
SARS-CoV-2: Severe Acute Respi ratory Syndrome Coronavirus 2
SOC: Standard of care
SRC: Safety review committee
t
1/2: half-life
VEEV: Venezuelan equine encephalitis virus ZIKV: Zika virus
Protocol EIDD-2801-2004
Ridgeback Biotherapeutics LP Version: 7.0
18 May 2021
Page 14 of 64
1. STUDY OBJECTIVES
1.1. Primary Efficacy ObjectivePrimary Efficacy Objective:To test whether orally adminis tered EIDD-2801 results in a grea ter proportion of clearance from 
nasopharyngeal (NP) swabs comp ared to placebo in hospitalized a dults by achieving undetectable (below 
the limit of detection [LOD] of the assay) viral RNA by Day 5 afte r initiation of study drug.
Primary Efficacy Endpoint: 
Achievement of undetectable (belo w the LOD of the assay) severe acute respiratory syndrome-
coronavirus-2 (SARS-CoV-2) RNA by Day 5 in NP swabs by quantitativ e reverse transcription 
polymerase chain reaction (qPCR). 1.2. Primary Safety Objective Primary Safety Objective:To evaluate the safety of trea tment with EIDD-2801 in participa nts diagnosed with COVID-19
Primary Safety Endpoints:
1. Adverse events (AEs)
2. Serious adverse events (SAE)3. Physical examinati on including vital signs
4. Safety laboratory assessments:
xcomplete blood counts (CBC) with differentials-decrease in hemoglobin ( Hgb) by >1 g/dL, or to <9 g/dL
-decrease in platelet  count by 50,000/Î¼L, or to <75,000/Î¼L
xcomprehensive metabolic panels  (CMP) including liver function t ests
-increase in aspartate aminotrans ferase (AST), alanine aminotrans ferase (ALT), amylase,
or lipase to Â•3x the upper limit  of normal (ULN)
xurinalysis
5. Electrocardiograms (ECGs)
1.3. Secondary Virologic Objective
To evaluate the efficacy of EIDD-2801 on clearance of SARS-CoV- 2 RNA.
Protocol EIDD-2801-2004
Ridgeback Biotherapeutics LP Version: 7.0
18 May 2021
Page 15 of 64
Secondary Virologic Endpoints:
1. Time to clearance of viral RNA in NP swabs 
-by qPCR  
2. The decline in viral RNA  by Day 3, Day 5, Day 8, Day 11, Day 15, Day 19, and Day 28 after 
initiation of study drug in NP swabs
-- by qPCR  
3. Rate of decline in viral RNA, (change in log 10copies/mL per day) in NP swabs
-- by qPCR  
1.4. Secondary Clinical Objectives 
To evaluate the effect of EIDD-2801 on improvement of clinical symptoms and signs of COVID-19.  
Secondary Clinical Endpoints:  
1. Peak stage on the World Healt h Organization (WHO) Ordinal Sca le for Clinical Improvement 
(Appendix 1)  OR clinical requirement for addition of other an tivirals including but not limited to:
-Pegylated interferon alpha
-Inhaled interferon beta1
-Ribavirin (any formulation)
-Any interleukin (IL)-6 inhibitor
2. Number of days of supplemental oxygen  
3. Number of days of mechanical ventilation4. Number of days in the Intensive Care Unit (ICU)5. Death
1.5. Exploratory Virologic Objective  
To evaluate the efficacy of EIDD-2801 to clear SARS-CoV-2 RNA a nd infectious virus .
Exploratory Virologic Endpoints:
1. Achievement of undetectable (be low the LOD of the assay) viral RNA titers by Day 5 in NP 
swabs
-by infectivity assay
2. Time to clearance of inf ectious virus in NP swabs 
-by infectivity assay
3. Clearance of infectious vir us by Day 3 and Day 5 in NP swabs 
-by infectivity assay
4. The number of acquired single- nucleotide polymorphisms in SAR S-CoV-2 genomes by Day 5 or 
Day 11 in NP swabs 
-by viral sequencing 
Protocol EIDD-2801-2004
Ridgeback Biotherapeutics LP Version: 7.0
18 May 2021
Page 16 of 64
1.6. Exploratory Clinical Objective
To ascertain the role of EIDD- 2801 in improvement of clinical s ymptoms and signs of EIDD-2801. 
Exploratory Clinical Endpoints:
1. Days of hospitalization
2. Time until on room air without r equirement for supplemental o xygen 
3. Time to resolution of COVID-19 symptoms defined as: 
-Fevers OR 
-At least one of the following symptoms: cough, shortness of bre ath, respiratory rate Â•20,
radiographic evidence of pneumonia OR
-other clinical symptoms or signs  that are not otherwise explain ed by comorbidities or co-
diagnoses 
4. Number of days until a 2-point decrease in stage according to  the WHO Ordinal Scale for Clinical 
Improvement (Appendix 1) .
5. Radiologic improvement by gradi ng chest diagnostics (when rad iography is available) 
6. Change in IL-6 levels by Day 5 
1.7. Pharmacokinetic Objectives
The pharmacokinetic (PK) objectives will be assessed on dosing Days 3 and 4 in participants enrolled at 
clinical sites able to conduct the collections. These sites inc lude but are not limit ed to  
 
Secondary:To evaluate EIDD-1931 PK in plasma in a subset of participants.    
Exploratory:To characterize the PK of EID D-2061 (NHC-TP) in peripheral blood  mononuclear cells (PBMC) in a 
subset of participants. Pharmacokinetic Endpoints: 
Secondary (plasma analysis):
1. Maximum EIDD-1931 concentration (C max) 
2. 1.5-hour EIDD-1931 concentration (C 1.5) 
3. 3-hour EIDD-1931 concentration (C 3) 
4. Area under the concentration:  time curve of EIDD-1931 (AUC) 
5. Elimination  half-life (t 1/2) EIDD-1931 

Protocol EIDD-2801-2004
Ridgeback Biotherapeutics LP Version: 7.0
18 May 2021
Page 17 of 64
Exploratory (PBMC analysis):
1. Maximum EIDD-2061 concentration (C max)
2. EIDD-2061 time of maximal concentration (t max)
3. Elimination half-life of EIDD-2061 (t 1/2)
4. Area under the concentrati on: time curve of EIDD-2061 (AUC 0-12)
5. Parent: metabolite (EIDD-1931: EIDD-2061) concentration ratio at each time point, in which both 
plasma and PBMC are processed for PK analysis
Protocol EIDD-2801-2004
Ridgeback Biotherapeutics LP Version: 7.0
18 May 2021
Page 18 of 64
2. BACKGROUND AND SCIENTIFIC RATIONALE
2.1. AbstractSARS-CoV-2 has infected over 5 million people worldwide since D ecember 2019, with >300,000 
fatalities reported as of the da te of this protocol (Johns Hopki ns University Coronavirus Resource Center: 
https://coronavirus.jhu.edu/map.html). In this unprecedented gl obal crisis, the medical community is 
lacking adequate tools to combat  the severe outcomes of COVID-1 9: respiratory collapse, multi-system 
organ failure, and death. There is a desperate need for safe an d effective antiviral therapies to mitigate the 
natural course of COVID-19, especially in those who are at high  risk for severe disease. Currently, there 
are no approved therapeutic s specific for COVID-19.  
EIDD-2801 (also known as MK-4482) i s an orally bioavailable pro drug of EIDD-1931, a small molecule 
ribonucleoside analogue that was de veloped for respiratory viru ses. EIDD-2801 has demonstrated potent 
in vitro antiviral activity agai nst a broad array of coronaviruses including SARS-CoV-2, Severe Acute 
Respiratory Syndrome Coronaviru s (SARS-CoV), and Middle East Re spiratory Syndrome-coronavirus 
(MERS-CoV), and it has shown in vivo activity in animal models of SARS-CoV and MERS-CoV 
(Agostini et al ,2019; Sheahan et al, 2020 ). EIDD-2801 is currently in P hase 1 clinical trials.  
We propose a Phase 2a randomized, placebo-controlled, double-bl inded clinical trial of EIDD-2801 in 
hospitalized men and women (age d 18+ years) with PCR-confirmed SARS-CoV-2 infection who also 
have evidence of symptomatic C OVID-19. We plan to enroll hospitalized patients who present within 7 
days of symptom onset for a 5-da y course of twice daily (BID) d osing of EIDD-2801 or placebo. We will 
follow participants for every hos pitalized day an d after they are discharged, for 28 da ys after the first 
dose. The primary endpoint will be  the achievement of undetecta ble (below the LOD of the assay) SARS-
CoV-2 RNA in NP swabs by Day 5 (end-of-treatment). Secondary cl inical endpoints will include the time 
until virologic clearance (by RNA testing), rate of decline in viral RNA, peak stage on the WHO Ordinal 
Scale for Clinical Improvement, requirement for additional anti virals, duration of ICU stay, duration of 
mechanical ventilation, or death. Safety outcomes will include AEs, SAEs, physical examination with 
vital signs, ECGs, and laborator y measurements (including CBC, CM P, and urinalysis). We will measure 
the PK of EIDD-1931, the primary c irculating form of EIDD-2801, in plasma. We will also collect 
PBMCs for measurement of EIDD- 2061 (NHC-TP), as an exploratory objective.  PK sampling will be 
assessed on  dosing days 3 and 4 in par ticipants enrolled at cli nical sites able  to conduct the collections. 
These sites include but are not limited to  
. We anticipate enrollment of 80 participants in this trial  at the following dose levels: EIDD-2801 
200 mg, EIDD-2801 400 mg, EIDD-2801 800 mg, and placebo.  In the p rimary analysis, we will compare 
the proportion of participants in each EIDD-2801 and placebo gr oups who achieve virological clearance.   

Protocol EIDD-2801-2004
Ridgeback Biotherapeutics LP Version: 7.0
18 May 2021
Page 19 of 64
2.2. Background 
COVID-19 is a disease caused by the  SARS-CoV-2 that was first d etected in Chinaâ€™s Hubei province in 
December 2019. It is a systemic disease with influenza-like symp toms; a subset of pat ients with severe 
disease can experience respiratory decline, acute respiratory d istress syndrome (ARDS), multi-system 
organ failure, and death. SARS-CoV-2 has infected over 5 millio n people worldwide since its emergence, 
with >300,000 fatalities reported a s of the date of this study protocol (Johns Hopkins University 
Coronavirus Resource Center: ht tps://coronavirus.jhu.edu/map.ht ml). 
There have been suggestions that the worst consequences of SARS-CoV-2 are seen in people with the 
highest viral burden ( Wolfel et al. 2020 ). Although numerous agents are currently being tested in clini cal 
trials, the majority of these are re-purposed drugs that are not specifically develope d for SARS-CoV-2 or 
other coronaviruses. There is a n urgent need for direct-acting SARS-CoV-2 antiviral  agents that can be 
used in patients to mitigate the worst complications of the inf ection. 
SARS-CoV-2 is an enveloped, posi tive-sense, single-strand RNA be ta-coronavirus that is related to 
SARS-CoV and distantly to MERS-CoV. SARS-CoV-2 has a genome of ~30kb which comprises 4 
structural proteins and 16 non-st ructural proteins. Among the n on-structural protei ns is nsp12, the RNA-
dependent RNA polymerase (RdRp) t hat is required to replicate the viral genome. Many successful 
antivirals for other viruses ta rget the RdRp: nucleos(t)ide inh ibitors for Human Immunodeficiency Virus 
(HIV)-1 and hepatitis B , NS5B inhibitors f or hepatitis C.  Howe ver, many nucleoside analogues fail to 
inhibit coronaviruses because of the unique coronavirus 3'-5' exoribonuclease (nsp14) that confers proofreading activity to the Co V RdRp. Only 2 nucleoside analog ues to date have been shown to 
overcome the coronavirus proofreading activit y and inhibit a br oad range of coronaviruses: remdesivir 
and EIDD-2801/EIDD-1931 ( Agostini et al, 2018 ; Agostini et al, 2019 ). 
EIDD-2801 (also known as MK-4482) i s an oral prodrug of EIDD-1931 ([N4-HYDROXY- Þ‰-O-(2-
METHYLPROPANOYL)CYTIDINE, NHC] , a novel small mo lecule ribonucleoside analogue with 
potent in vitro inhibition of a broad array of c oronaviruses including SARS-Co V-2, SARS-CoV, and 
MERS-CoV ( Sheahan et al, 2020 ). EIDD-2801 is converted into its  circulating intermediate form , EIDD-
1931, by non-specific esterases in pla smaâ€”this is the primary f orm found in systemic circulation. EIDD-
1931 is then taken up by target m ononuclear cells and enzymatic ally converted by host kinases to the 
metabolites 5â€™-monophosphate EIDD-1931 and 5â€™-triphosphate EIDD -1931 (also called EIDD-2061, or 
NHC-TP). The 5â€™-triphosphate form is a competitive antagonist o f the RNA-dependent RNA polymerase 
(RdRp), while the 5â€™- monophosphate form promot es lethal mutagen esis in the nascent viral RNA strand,
thus impacting downstream viral processes. EIDD -1931 has a media n effective concentration (EC
50)o f  
0.3 micromolar agai nst SARS-CoV-2 in vitro , demonstrating a 1000-fold reduction in SARS-CoV-2 viral 
titers, as well as reduced lung hemorrhage and damage in a muri ne model of SARS-CoV. 
Protocol EIDD-2801-2004
Ridgeback Biotherapeutics LP Version: 7.0
18 May 2021
Page 20 of 64
Pharmacologic aspects of EID D-1931 and its metabolites have bee n evaluated in in vitro cell culture 
systems, as well as pre-clinical  animal models. Anabolic PK asse ssments were characterized in cultured 
human bronchial tracheal epith elial cells.  Following ex vivo i ncubation of epithelia l cells with 20 Î¼M
EIDD-1931, there was rapid convers ion to the EIDD-1931 metaboli te (EIDD-Triphosphate, EIDD-TP) 
within the first 60 minutes.  Pla teau concentrations of EIDD-TP  (4 nmol/106cells) were achieved within 4 
hours and remained stable for  24 hours.  Removal of drug led to persistence of the metabolite over a 24-
hour period.  The estimated intracellular half-life (t 1/2) of EIDD-TP was 4 hours.  Comparable kinetics 
were observed in mouse lung tissue post-administration of an oral 500 mg/kg dose.   
The orally bioavailable is opropylester compound, EIDD-2801, has been evaluated in an ongoing, Phase 1,
randomized, double-blind, placebo-controlled single-ascending a nd multiple-ascending dose first in-
human study to assess its safet y, tolerability, and PK.  A total of 130 healthy participants (109 males and 
21 females) received at least  1 dose of EIDD-2801 or placebo in the Phase 1 trial EIDD-2801-1001. 
Preliminary, unblinded safety data are available for all subjec ts. Review of these safety data indicates that 
single oral doses of up to 1600 mg EIDD-2801 or placebo and mul tiple oral doses of up to 800 mg EIDD-
2801 or placebo Q12H for 5.5 days have  been generally well tole rated in healthy participants.  Further 
details are provided in Section 2.3.1.
The prodrug (EIDD-2801) was genera lly not detectable in plasma following single (50 to 1600 mg) or 
multiple doses (50 to 800 mg B ID for 5.5 days) of MK-4482.  Pla sma concentrations of the nucleoside 
metabolite (EIDD-1931)  were detectable.  T maxoccurred approximately 1 hour post dose.  Plasma EIDD-
1931 concentrations generally dec lined in a monophasic manner, w ith a t 1/2 of approximately 1 hour.  A
biphasic profile with a later , slower elimination phase (t 1/2 ranging from 1.47 to 19.2 hours) was observed
in some participants (follo wing single doses of 1200 mg and 160 0 mg and following multiple doses of 
600 mg and 800 mg).  C max and AUC increased in an approx imately dose-proportional manner  across the 
range of doses tested.  No accumulation occurred following mult iple dosing (Q12H for 5.5 days), and 
administration in the fed state di d not meaningful ly impact plas ma exposure of EIDD-1931. There were 
no significant detectable concen trations of EI DD-2801; initial PK parameters were identified for EIDD-
1931 concentrations in plasma.  Fol lowing multiple doses of 100  mg BID EIDD-2801 orally in the fasted 
state, median t max was 1.25 hours post-dose (range 1-2 hours), and concentrations  declined 
monophasically and were quantifia ble until the 6 to 9-hour time points. The apparent terminal half-life 
(t1/2) was 0.918 and 0.969 hours on Days 1 and 6, respectively. AUC tau was 853 ng*h/mL (%CV 19.9), 
and C max was 395 ng/mL (%CV 18.5). The increase in exposure between the 50 mg and 100 mg doses 
was slightly supraproportional with the 2-fold increase in dose resulting in a 2.23-fold increase in AUC tau
and 2.31-fold increase in Cmax. (EIDD-2801 Investigatorâ€™s Brochure, V3.0, 2020). 
2.3. Known Potential Risks2.3.1. Clinical FindingsEIDD-2801 has been studied in a sin gle and multiple dose escala tion study in humans that includes a food 
effect cohort. All subjects have c ompleted participation in the  study and preliminary data are available. 
A total of 130 healthy volunteers  were enrolled in this study. Sixty-four participants received a single 
dose between 50 and 1600 mg EIDD-2801 or placebo; 56 participants received multiple doses between 
50 and 800 mg EIDD-2801 or placebo BID for 5.5 days; and 10 par ticipants received a single dose of 
Protocol EIDD-2801-2004
Ridgeback Biotherapeutics LP Version: 7.0
18 May 2021
Page 21 of 64
200 mg EIDD-2801 in the fed state  followed by a single dose of 200 mg EIDD-2801 in the fasted state 
after a washout period o f 14 days, or vice versa.  
Among participants who receive d single doses of EIDD-1801 or placebo, a greate r proportion of 
participants reported AEs fo llowing administr ation of placebo ( 43.8%) than following  administration of 
EIDD 2801 (35.4%). One moderate A E (headache) was reported by 1  participant follow ing administration 
of EIDD-2801 at the 400-mg dose le vel, and 2 moderate AEs (naus ea and headache) were reported by 1 
participant following a dministration of plac ebo. No severe AEs were reported. The most frequently 
reported AE was headache, which was reported by 18.8% of partic ipants who were admin istered placebo 
and 12.5% of participants who w ere administered EIDD-2801.  
Among participants who received multiple ascending doses of EID D-2801 or placebo BID over 5.5 days, 
a greater proportion reported A Es following administration of p lacebo (50.0%) than following 
administration of EIDD-2801 (42.9%). With the exception of 1 pa rticipant in the 200 mg BID group who 
reported moderate AEs of sore th roat, aching limbs, and flu-lik e symptoms, all other AEs were mild in 
severity. The most frequently re ported AE was diarrhea, which w as reported by 7.1% of participants who 
were administered EIDD-2801 and 7. 1% of participants who were a dministered place bo. One participant 
had an AE of mild, truncal, maculopapular, pruritic rash follow ing multiple doses of 800-mg EIDD 2801, 
which was considered by the inve stigator to be related to the s tudy drug; this AE resulted in early 
discontinuation of the st udy drug dosing on Day 3. The particip ant was administered a  topical steroid and 
anti-histamines, and the AE resolved after 18 days.  
Among participants in the food-eff ect evaluation, 3 participant s reported 1 AE each, all of which were 
mild in severity.  There were no serious AEs reported in this study and there were no trends of increased frequency or 
severity of AEs with higher doses of EIDD-2801.  
There were no clinically signifi cant findings in clinical laboratory, vital signs, or ECG data.  
 
(Section 2.3.2.2) .  However, no 
clinically significant changes in hematologi cal parameters were seen in the Phase 1 study.  
2.3.2. Nonclinical Findings
 
 
 
2.3.2.1. Effects on the Gastrointestinal Tract
 

Protocol EIDD-2801-2004
Ridgeback Biotherapeutics LP Version: 7.0
18 May 2021
Page 22 of 64
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.3.2.2.
 
 
 
 
 
 
 
 

Protocol EIDD-2801-2004
Ridgeback Biotherapeutics LP Version: 7.0
18 May 2021
Page 23 of 64
 
 
 
2 3. E r
 
 
 
 
 
 
 
 
 
  
 
 
 
      

Protocol EIDD-2801-2004
Ridgeback Biotherapeutics LP Version: 7.0
18 May 2021
Page 24 of 64
2.3.2.4.
 
 
 
 
 
 
2.3.2.5.
2.3.2.5.1.
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Protocol EIDD-2801-2004
Ridgeback Biotherapeutics LP Version: 7.0
18 May 2021
Page 25 of 64
 
 
 
 
2.3.2.5.2.
 
 
 
2.3.2.5.3.
 
 
 
 
 
 
 
 
2.3.3.
 
 
 
 

Protocol EIDD-2801-2004
Ridgeback Biotherapeutics LP Version: 7.0
18 May 2021
Page 26 of 64
 
 
 
 
 
 
 
 
 
 
 
 
2.4.
Known Potential Benefits
EIDD-2801 has been administered to COVID-19 patients in ongoing  studies and the safety and 
tolerability of single and multiple ascending doses has been te sted in healthy adult volunteers (See 
Section 2.3.1) . 
After oral delivery, EIDD-2801 i s rapidly hydrolyzed by circulating esterases to produce high circulating 
(plasma) levels of EIDD-1931.  In c ell culture systems, EIDD-19 31 has been shown to inhibit replication 
of multiple viral pathogens from multiple RNA virus families in cluding pathogenic CoV (e.g., SARS-
CoV-2, severe acute respiratory syndrome (SARS-CoV), and Middle East Respiratory Syndrome 
(MERS)), influenza viruses (seasonal, pandemic, and avian subty pes), respiratory syn cytial virus (RSV), 
alphaviruses (e.g., Eastern equine encephalitis virus (EEEV), V enezuelan equine encephalitis virus 
(VEEV), and Chickungunya virus (CHK V)), Filoviruses (e.g., Ebol a virus (EBOV), and Zika virus 
(ZIKV)). In addition, EIDD-2801 i s active against orthopox viru ses probably because orthopox viruses 
encode their own unique RNA polymerase. Antiviral activity has been verified in an imal models of CoV 
(MERS- and SARS-CoV), influenza,  RSV, VEEV, CHKV, and EBOV. The  primary mechanism of action 
of EIDD-2801 is inhibition of vira l RNA replication by incorporation of EIDD-1931 monophosphate 
metabolite into the viral RNA ge nome resulting in induction of viral error catastrophe.  
2.4.1. Potential Benefits of Treatment 
EIDD-2801 has demonstrated activit y against SARS-CoV-2 in vitro , and SARS-CoV as well as MERS-
CoV in vitro and in vivo. EIDD- 2801 has shown efficacy against CoV in animal models.  In mice, EIDD-
2801 was active in both a prophylactic and therapeutic setting ( Painter et al, 2019 ). When EIDD-2801 was 
administered up to 24 hours after infection w ith SARS-CoV or up to 12 hours after in fection with MERS-
CoV, a reduction in viral lung titers, protection from both lun g hemorrhage and weight loss, and 
improvements in pulmonary function were seen, compared to vehicl e-treated (control) animals.
Nonclinical findings suggest tha t it will be activ e agains
t SAR S-CoV-2.  More inf ormation regarding 
nonclinical activity o f EIDD-2801 can be found in the Investiga torsâ€™ Brochure. 

Protocol EIDD-2801-2004
Ridgeback Biotherapeutics LP Version: 7.0
18 May 2021
Page 27 of 64
2.4.2. Potential Benefits of Clinical Monitoring and Virologic Testing
Participants enrolled in the st udy will undergo close clinical a nd laboratory monitoring that could 
facilitate improved management  of COVID-19 with associated bene fit to the individual, their family, and 
the community at large.
Protocol EIDD-2801-2004
Ridgeback Biotherapeutics LP Version: 7.0
18 May 2021
Page 28 of 64
3. PATIENT POPULATION
Adults aged 18 years or older w ho are hospitalized with a new diagnosis of COVID-19 with a duration of 
symptoms Â”7 days. Patients requiring admis sion to an intensive care unit f or mechanical ventilation are 
not eligible. Persons with Low E nglish Proficiency (LEP) and who are non-English Speakers may join. 
3.1. Inclusion Criteria for EnrollmentParticipants who meet all the following criteria will be eligibl e for study participation:
1. Has COVID-19 disease, define d by having one or more of the following new symptoms and signs 
(within 7 days):
-Fevers OR 
-At least one of the following: cough , sore throat, shortness of breath, respiratory rate Â•20,
radiographic evidence of pneumonia OR
-Anosmia OR
-other clinical symptoms or signs  of COVID-19 that are not otherwi se explained by 
comorbidities or co-diagnoses
2. PCR+ test for SARS-CoV-2 with in 6 days prior to randomization.
3. Has new signs or symptom s of COVID-19 that began Â”7 days of anticipated first dose of study 
drug.
4. Persons Â•18 years old.
5. Is an inpatient at the time of first dose.6. Is willing and able to compl y with all study procedures inclu ding providing informed consent
firsthand or via a legally author ized representative, collectio n of virology samples, and any safety 
tests that are not included as pa rt of standard of care (SOC).
7. Is willing and able to take oral  medications and is anticipate d to be able to take the full course of 5 
days of study drug.
Pregnancy and Contraception:
 
T
herefo re, treatment with EIDD-2801 is  contraindicated in women who 
are pregnant or nursing and in the  male partners of women who a re pregnant. Extreme care must be 
taken to avoid pregnancy during the  study and for 4 days after completion of EIDD-2801 dosing in
female participants and for 4 days after completion of EIDD-2801 dosing in female partners of male 
participants.
8. A female participant is eligib le to participate if she is not  pregnant or breastfe eding and at least 
one of the following conditions applies: 
xIs not a woman of childb earing potential (WOCBP)
OR
xIs a WOCBP and using a contraceptive method that is highly effe ctive (a low user 
dependency method OR a user-dep endent method in combination with a barrier method), 

Protocol EIDD-2801-2004
Ridgeback Biotherapeutics LP Version: 7.0
18 May 2021
Page 29 of 64
or be abstinent from heterosexual intercourse as their preferre d and usual lifestyle 
(abstinent on a long-term and pers istent basis), as described in Appendix 2 during the 
intervention period and for at leas t 4 days after the last dose of study intervention. The 
investigator should evaluate the  potential for contraceptive me thod failure (ie, 
noncompliance, recently initiated ) in relationship to the first  dose of study intervention.
xA WOCBP must have a negative high ly sensitive pregnancy test (s erum test is required) 
within 24 hours before the first  dose of study intervention. 
xAdditional requirements for pr egnancy testing during and after study intervention are 
located in Section 4.4. 
xThe investigator is responsible for review of med ical history, menstrual history, and recent 
sexual activity to decrease the ri sk for inclusion of a woman w ith an early undetected 
pregnancy. 
xContraceptive use by women should be consistent with local regu lations regarding the 
methods of contraception for those participating in clinical st udies.
xGiven the elevated risk of venous  thrombotic events in patients hospitalized with 
COVID-19 ( Benson et al 2020 ; Spratt et al 2020 ), estrogen-containi ng contraceptives must 
not be started to fulfill the contraceptive requirement of this  study at any time during 
participantâ€™s hospita lization. If contraceptives are interrupte d as standard of care 
management of COVID-19 patients and resumed at a later time point, such as at hospital 
discharge, then abstinence must  be practiced for the defined period of back-up 
contraception per the contrace ptive product la beling. After thi s period, contraceptive use 
must adhere to  Appendix 2.
9. Male participants are eligible  to participate if they agree to the following during the intervention 
period and for at least 4 days af ter the last dose of study inte rvention: 
xBe abstinent from hete rosexual intercourse as their preferred a nd usual lifestyle (abstinent 
on a long term and persistent basi s) and agree to remain abstin ent 
OR
xMust agree to use contraception un less confirmed to be azoosper mic (vasectomized or 
secondary to medical cause [Appendix 2] ) as detailed below:
Agree to use a male condom plus  partner use of an additional co ntraceptive method when having 
penile-vaginal intercourse wit h a WOCBP who is not currently pr egnant. Note: Men with a 
pregnant or breastfeed ing partner must agree  to remain abstinent from penile-vaginal intercourse 
or use a male condom during each e pisode of penile-vaginal pene tr
ation.
xContraceptive use by men should be c onsistent with local regula tions regarding the 
methods of contraception for those participating in clinical st udies.
3.2. Exclusion Criteria for Enrollment
Participants who meet any of the following criteria will not be  eligible for participation
1. Is anticipated to require ICU a dmission for mechanical ventila tion within 24 hours of enrollment. 
2. Requires more tha n 6 liters/minute of oxygen to maintain O 2 saturation above 95%. 
3. Is not expected to sur vive longer than 24 hours. 
Protocol EIDD-2801-2004
Ridgeback Biotherapeutics LP Version: 7.0
18 May 2021
Page 30 of 64
4. Has a platelet count less than 100,000/Î¼L, hemoglobin <9 g/dL,  or has a disorder of the 
hematologic system including a nemic disorder or other blood dyscrasia, cancer of the hematologic 
system, history of bone marrow tran splant, or other significant  hematologic disease.
5. Women who are pregnant or breastfeeding.
6. Is experiencing DAIDS AE gradi ng scale grade 4 baseline medic al conditions or laboratory 
abnormalities.
7. Has received a vaccine for COVID-19 prior to enrollment, or plan s to receive a vaccine for 
COVID-19 before the end-of-study visit.
8. Has received an experimental a ntiviral treatment for COVID-19 prior to enrollment.
9. Has received convalescent plas ma or other monoclonal antibodies prior to e nrollment.
10. Is participating in another cl inical study that involves pharmacologic intervention or has 
participated in another study within 30 days of 5 half-lives of the investigational agent 
(observational study parti cipation is permitted).
11. In the opinion of the investig ator, has end-organ disease as  a result of relevant comorbidities: 
chronic kidney disease (reduced gl omerular filtra tion rate [GFR] <30 mL/min by the Modification 
of Diet in Renal Disease (MDRD) study equation prior to COVID-19 symptom onset),
decompensated chronic liver diseas e or cirrhosis, decompensated congestive heart failure, active 
peripheral vascular disease incl uding active diab etic ulcers, c hronic pulmonary disease prior to 
COVID-19 symptom onset requiring bilevel positive airway pressure  (BiPAP) or >4 L/min
supplemental oxygen at baseline; if using Â”4 L/min supplemental oxygen at baseline, consultation 
with and approval of the sponsor is required prior to enrollmen t. 
12. Has a diagnosis of cancer th at is not in remission.  Noninva sive cancers, such as basal and 
squamous cell carcinoma or hist ory of in situ tum ors are allowe d at the discretion of the 
investigator after disc ussion with the sponsor. 
13. Has received an organ transplantation.
14. Has received a bone ma rrow transplantation.
15. Has been on immunosuppressive medications within 1 month prior to enrollment.16. Has any condition that would, in the opinion of the investig ator, put the participant at increased 
risk for participati on in a clinical trial.
17. Has known active hepatitis C (H CV RNA positive), active hepati tis B (hepatitis B surface antigen 
positive), or HIV (ELISA and confirmatory Western blotting). New screening tests not required. 
18. Is currently taking nucleos(t )ide analogues for HIV or hepati tis B, or for their prevention, within 
30 days of study enrollment.
19. Is currently taking systemic c orticosteroids other than replacement doses or for treatment of 
COVID-19.
20. Has a body mass index (BMI) >50 kg/m
2.
21. Is anticipated to require s urgery within 48 hours after hosp ital admission.
Protocol EIDD-2801-2004
Ridgeback Biotherapeutics LP Version: 7.0
18 May 2021
Page 31 of 64
22. Is anticipated to have an NPO (nothing per mouth) order plac ed within 48 hours after hospital 
admission that is e xpected to last for Â•24 hours.
Protocol EIDD-2801-2004
Ridgeback Biotherapeutics LP Version: 7.0
18 May 2021
Page 32 of 64
4. INVESTIGATIONAL PLAN
4.1. Definitions
I. Enrolled: From time consent ed to initiation of study drug unti l designated as off study 
either through discontinuation or completion of the study.
II. Randomized: when a patient iden tification (ID) number is assi gned through randomization.
III. Screen Failures: signed informed consent, but then determin ed to be ineligible or 
withdraws before initiation of study drug.
IV. Discontinued: randomized, but  then withdrawn by investigator  or withdraws consent.
V. Completed: Participants are c onsidered completed when they are  followed through to Day
28 or died before that. 
4.2. Randomization and BlindingThis study will be conducted in up to 4 parts.  During Part 1, participants will be randomized in a 1:1:1 
ratio to EIDD-2801 200 mg BID, EIDD-2801 400 mg BID, or placebo BI D; during Part 2, approximately 
21 participants will be randomiz ed in a 2:1 ratio to EIDD-2801 400 mg BID:placebo BID; during Part 3, 
approximately 21 participants wil l be randomized in a 2:1 ratio to EIDD-2801 800 mg BID:placebo BID.
An optional Part 4 may be adde d during which approximately 21 pa rticipants will be randomized in a 2:1
ratio to EIDD-2801 BID:placebo B ID and the dose of EIDD-2801 may  be the same or lower than doses 
studied in previous Part(s), but not to exceed 800 mg BID.
The study parts will be conducted a s follows:  Part 1 of the st udy may be terminated upon approval and 
implementation of Protocol Amen dment 3, and Part 2 will be initiated immediately there after.  Part 3 will 
be initiated once Part 2 has bee n fully enrolled.  If initiated,  Part 4 may begin enrolling participants as
soon as Part 3 has been full y enrolled.  Study Parts 2 and 3 ma y be terminated prematurely based on 
emerging data from this and othe r ongoing studies of EIDD-2801.
On Day 1, participants will be assigned a unique ID number (rand omization number). The randomization 
number encodes the pa rticipantâ€™s assignmen t to one of the group s of the study, according to a
randomization schedule generate d prior to the start of each indi vidual study part. Each participant will be 
dispensed blinded study drug, la beled with his/her unique random ization number, throughout the study.
In case of an emergency, the inve stigator has the sole responsibility for determini ng if unblinding of a 
participantsâ€™ study drug assignmen t is warranted. Participant sa fety must always be the  first consideration 
in making such a deter mination. If the inves tigator decides that unblinding is warrante d, the investigator 
should make every effort to contact the sponsor prior to unblin ding a participantâ€™s study drug assignment 
unless this could delay emergenc y treatment of the participant. If a participantâ€™s study drug assignment is 
unblinded, the sponsor must be no tified within 24 hours after b reaking the blind. The date and reason that 
the blind was broken must be rec orded in the source documentati on and case report form , as applicable. If 
the investigator decides th at unblinding is warranted, unblinding of a participantâ€™s study drug assignment 
will be coordinated by the unbli nded pharmacist for the study. 
Protocol EIDD-2801-2004
Ridgeback Biotherapeutics LP Version: 7.0
18 May 2021
Page 33 of 64
4.3. Intervention
4.3.1. ScreeningAdult patients who are newly hospitalized with PCR-confirmed SA RS-CoV-2 and evidence of 
symptomatic COVID-19 will be invite d to participate in the stud y. Those who express interest will 
undergo the informed consent proc ess and be given the chance to  ask any questions before agreeing to 
participate. Those who consent t o participate will undergo screening for study entry; the time between 
screening and study entry should be  as short as possible (ideal ly the same day, but no longer than 48 
hours). Screening assessments will include demographics, medica l history, concomitant medications, 
review of inclusion and exclusio n criteria, height, weight, BMI,  physical examinatio n including vital 
signs, clinical chemistry labs (C MP), hematology (CBC with differe ntial), high sensiti vity serum beta-
human chorionic gonadotropin (HCG) (to rule out pregnancy) as appl icable, urinalysis, electrocardiogram
(ECG), and pulse oximetry. It is exp ected that measurements/val ues will have been obtained as SOC, and 
medical chart extraction will  be performed. Missing values will be obtained as part of study procedures. 
Any chest radiography results fro m hospital admission will be recorded. 
4.3.2. Administration of Study DrugsUpon completion of baseline asse ssments (including virologic as sessments below), participants will then 
be administered the first dose of study drug (EIDD-2801 or placeb o). Each participant will begin study 
treatment dosing with the first dose on the morning of Day 1, i f possible. If the first dose is given later in 
the day, the second dose may be give n at least 4 hours later on  Day 1. Study drug administration will 
continue BID for a total of 5 days (10 doses). If the first dos e on Day 1 is given in the late evening, the 
second dose may be taken on the mor ning of Day 2, in which case the final dose will be taken on the 
morning of Day 6.  In the event of missed doses, if the total number of missed dose s is 4 or fewer, the number of days of 
study drug can be extended by no more than 1 day (through Day 6) w ith the equivalent of missed doses 
up to 2 doses. If the participant misses more than 4 consecutive  doses, or more than 5 total doses, then the 
participant will be d iscontinued from any further study drug ad ministration and followe d for safety for the 
remainder of the study. Missed dos es and times of administration  will be recorded. 
If a participant cannot ingest cap sules orally during the study p eriod, capsules will be opened, and the 
powder will be mixed with water  and administered by mouth or th rough a nasogastric, percutaneous 
endoscopic gastrostomy (P EG) or orogastric tube.
4.3.3. Virologic Assessments
Upon enrollment, participants w ill have 2 NP swabs performed, one in each nostril (R or L to be 
documented), accessing the posterior nasopharynx. The NP swabs will be collected an d stored separately 
for laboratory analysis. On Days 3, 5, 8, 11, 15 (inpatients only),  19 (inpatients only), and 28, participants 
will also have 2 NP swabs performed in the same way, collected a nd stored identically and individually.
One swab will be sent to an infectivity lab for analysis. The ot her swab will be sent to  for PCR 
sequencing.  Detailed instructions  for preparation and shipment of samples will be pr ovided in a separate 
document. 

Protocol EIDD-2801-2004
Ridgeback Biotherapeutics LP Version: 7.0
18 May 2021
Page 34 of 64
In the setting of bronchoalveolar  fluid lavage with sampling, o r in participants who require mechanical 
ventilation who have endotracheal tube fluid sampling, we will collect a portion to perform viral RNA 
testing and the infectivity assay on t he sample. If available fr om SOC procedures, a sample of sputum will 
also be collected if the part icipant has a productive cough and  used to perform viral RNA testing and 
infectivity assays.  In addition, a portion of material from NP  swabs will be archived and frozen for viral 
sequencing.  
4.3.4. Clinical AssessmentsOn each day that virology sampl es are obtained, participants wi ll be assessed for clin ical endpoints and 
interim AEs (and SAEs). Chart r eview will occur on structured days to perform safety assessments and 
record concomitant medications ( including antivirals). CMP, CBC w ith differential, and urinalysis will be 
recorded at regular intervals  during the study as indicated in the Schedule of Events (see Section 7.1).
Any results that are not availa ble will be obtained on the applicable chart extraction day.
Participants who are discharged from the hospital during study participation will return to the clinic for 
study visits through the Day 28 visit. Clinic visits will occur on Days 3, 5, 8, 11, and 28.  On Day 15 
(Â±1 day), a member of the study s taff will contact the participa nt by telephone to query them about 
symptoms, study drug adherence, and  concomitant medications. Ou tpatients will be seen in one of several 
locations, including but not lim ited to COVID-19 ambulatory pods, COVID-19 ambulatory clinics and 
clinical research units, and home vi sits. In all cases, visits will conform to infection control practices that 
are established by the institution. If the participant is disch arged to a secondary car e facility, study site
staff will take measures to meet i nstitutional regulatory requir ements of the primary site as well as the 
receiving site to continue coll ecting study-related samples where allowed. 
During in-clinic study visits, pa rtial pressure of oxygen (PO2)  will be measured by oximetry, and oral 
temperature will be documented. Other vital signs will be asses sed, and a targeted physical examination 
will be conducted as needed.  AEs and concomitant medications w ill be collected that have occurred since 
the last visit/report. Safety lab assessment (CBC with different ial, CMP, and urinalysis) will be 
conducted, and for women of chil dbearing potential, a high sens itivity serum pregnancy test will be 
performed at the end-of-study (EO S) visit or at early discontinua tion. Results of a single post-dose ECG 
should be recorded.  If the partic ipant is discharged from the hospital before a post-dose ECG is recorded, 
and recording of an outpatient ECG i s not feasible, then result s of the last record ed ECG before hospital 
discharged will be entered into the CRF. The results of any chest diagnostics done as part of SOC will be 
recorded. Any SAEs will be followed for 30 days after the end of study participatio n as detailed in 
Section 8.10.3.
Participants who are discharged f rom the hospital before the EO S visit will continue to take study drug at 
home for the full 5 day course, and drug accountability will be  conducted at the Day 5 and/or Day 8
interim study visits, where allowed by the study institution.  Participants will be instructed on how to 
report worsening of disease, including development of any addit ional symptoms of pneumonia or other 
concerning illness that may requi re interim assessment includin g clinic or urgent v i
sits. 
4.4. Pregnancy TestingPregnancy testing: 
Protocol EIDD-2801-2004
Ridgeback Biotherapeutics LP Version: 7.0
18 May 2021
Page 35 of 64
â€¢ Pregnancy testing requirements for study inclusion are describ ed in Section 3.1.
â€¢ High sensitivity pregnancy tes ting should be conducted at scre ening (a serum test is required) 
within 24 hours of the first  dose of study drug and on Day 28 a pproximately 23 days after the
last dose of study intervention. 
â€¢ Additional serum or urine pregnancy tests may be performed, as  determined necessary by the 
investigator or required by local  regulation, to establish the absence of pregnancy at any time 
during the subject's participation in the study.
4.5. Serology 
Serology testing will be performed on plasma for IL-6 levels on Day 1 (pre-dose), Day 5, and Day 19.
Samples will be archived for fur ther cytokine testing in the fu ture.  
4.6. Rationale for Medication Dosing 
 
 
 Although 3 doses were effective in influenza 
models, the prolonged viral shedd ing that has been described in  COVID-19 indicates th at a longer dosing 
period may be beneficial. Also, a llowing for differences betwee n animal models and human disease, a 
margin of exposure at the top end of  the range is desirable. Do ses up to 800 mg twice daily are considered 
important to study in order to allo w for sufficient exposure ba sed on the use of data extrapolated from 
other species. Exploring a range of doses will allow for the se lection of the best dose( s) to carry forward 
into subsequent studies.  
Review of preliminary, unblinded data indicates that a treatment  course of 5.5 days has been generally 
safe and well tolerated at mu ltiple ascending doses (MAD) up to  800 mg, covering the doses planned for 
this efficacy/safety study.  Also, single ascending doses (SAD)  up to 1600 mg were si milarly well 
tolerated, and PK has been dose-proportional in all cohorts. Refer to the IB for full information regarding 
animal efficacy studies and scal ing to humans. Definition of an Overdose for this Protocol 
For purposes of this protocol, an overdose is a single dose of more than 800 mg. 
4.7. Concomitant Medications
Nucleos(t)ide analog drugs that are used for the treatment or p revention of HIV or hepatitis B virus are 
prohibited during the study, as are vaccines against COVID-19. Remdesivir will be permitted. Corti costeroids for the treatment  of COVID-19 will be permitted.  
4.8. Study Discontinuation 
If a participant is withdrawn from the study, the reason for wi thdrawal and the date the participant was 
removed will be documented in the case report form (CRF). A par ticipant must be disc ontinued from the 
trial for any of t he following reasons:

Protocol EIDD-2801-2004
Ridgeback Biotherapeutics LP Version: 7.0
18 May 2021
Page 36 of 64
xThe participant or legal represen tative (such as legal guardian)  withdraws consent.
xIntercurrent illness that prevents further administration of tr eatment. 
xSevere or life-threatenin g EIDD-2801-related AE(s). 
xIf in the opinion of the Investigator, a change or temporary or permanent discontinuation of 
therapy would be in the best interest of the participant. 
xNoncompliance with trial treatme nt or procedure requirements.
xParticipant is lost to follow-up. 
xParticipant becomes pregnant. 
If a randomized participant with draws from the study and has not been administered a dose of study drug 
or placebo, they will be replaced. A dditional participants may be randomized, if needed, to ensure that an 
adequate number of participant s provide Day 5 efficacy data. 
Whenever possible, participant s should continue to be monitored  for safety through the  remainder of the 
study.   
The investigator should make ev ery effort to perform the assessments indicated for the End-of-Study visit 
(see the Schedule of Events; Section  7.1) for participants who disconti nue early from the study.  
Protocol EIDD-2801-2004
Ridgeback Biotherapeutics LP Version: 7.0
18 May 2021
Page 37 of 64
5. PHARMACEUTICAL INFORMATION
5.1. Agent AccountabilityThe study drug will be provided by the sponsor.The study site will acknowledge receipt of study drug supplied by the sponsor by returning the 
appropriate documentation form to confirm the shipment conditio n and content. Any damaged shipments 
will be replaced.An accurate drug disposition record will be kept, specifying al l study drug received, dispensed, returned 
to the sponsor, and disposed of by t he study site. This drug ac countability record wil l be available for 
inspection at any time, and at th e completion of t he study, the  original drug accountability record will be 
available for review by the sponsor upon request.5.2. Mode of ActionThe mechanism of antiviral activity of EIDD-2801 is â€˜lethal muta genesisâ€™, a concept that is predicated on 
increasing the viral mutation rate beyond a biologically tolerab le threshold, resulti ng in impairment of 
viral fitness and leadi ng to viral extinction.
The specifics of the mechanism a re as follows: EIDD-2801 is rapi dly taken up by cells and the 
ÆLVRSURS\OHVWHUFOHDYHGW o liberate EIDD-1931, which is in  turn phosphorylated to EIDD-2 061 by host 
NLQDVHV7KHÆWULSKRVSKDWH EIDD-2061, acts as a competitive, alternative substrate for vir ally-encoded 
RNA-dependent RNA polymerases, and EIDD-2061 is incorporated int o nascent viral RNA. Owing to the 
ability of the N4hydroxycytosine ba se of EIDD-1931 to tautomeriz e, EIDD-2061 can pair with either 
guanosine or adenosine, and consequently can substitute for eit her cytidine triphospha te (CTP) or uridine 
triphosphate (UTP), respectively. This results in an accumulation of mutations, which increase with each 
cycle of viral replication. The  process whereby the mutation ra te is increased by expo sure to a drug is 
referred to as viral decay accel eration and results in viral ablation.
Significant work has gone into valid ating this mechanism of action for EIDD-2801/1931, and it has been 
shown for MERS-CoV, VEEV, and inf luenza A virus (IAV) that viru ses grown in the presence of EIDD-
1931 have significantly increased l evels of transition mutations . Multi-log decreases in virus yields were 
observed after treatment wit h EIDD-1931. Additionally, it was d emonstrated for VEEV that the 
infectivity of virions formed in the presence of EIDD-1931 decre ases from approxim ately 20% to <0.2%, 
and that the infectious virions  are significantl y impaired in t heir replication ability. As a consequence of 
this mechanism of action, the ge neration of drug-resistant esca pe mutants is practica lly impossible. This
same effect was demonstrated for  CoV and influenza virus. Furthermore, given the un ique mechanism of 
action, EIDD-2801 is expected to be active against viruses resistant to other antiviral agents which have a 
different mechanism of action. T he only data generated to date regarding the activity of EIDD-1931
against viruses resistant to other nucleoside analogs found tha t EIDD-1931 was active against CoV 
resistant to remdesivir in cell culture assays.
As an alternative or additional m echanism of action, it has been theorized that incorporation of 
EIDD-2061 into viral genomic RNA ca n change the thermodynamics of RNA secondary structure and 
Protocol EIDD-2801-2004
Ridgeback Biotherapeutics LP Version: 7.0
18 May 2021
Page 38 of 64
thus decrease the efficiency of the promoter regions involved i n RNA genome replication. Further details 
regarding the mechanism of action of EIDD-2801 are provided in the IB.
5.3. Description
EIDD-2801 is a white to off white solid.EIDD 2801 (100- and 200-mg capsules) and matching placebo will b e supplied as dry fil led capsules for 
oral administration, a long with the batch/l ot numbers and Certi ficates of Analysis. Doses of EIDD-2801
or matching placebo will be admin istered as combinations of 100 - and 200-mg capsules in such a way as 
to preserve the study blind and as appropriate for the dose lev el.
5.4. Packaging The study drug will be labeled in accordance with regulatory requirements and will be stored according to 
the instructions on the label, i n a location that is locked wit h restricted access.
5.5. Storage
Study drug should be stored in a secure, locked, restricted acc ess facility at controlled room temperature 
defined as 15Â°C to 25Â°C (59Â°F to 77Â°F). Excursions are permitte d up to 30Â°C (86Â°F) for up to 24 hours. If 
excursions occur which are outsi de of this range, the pharmacy staff should contact the sponsor to 
determine the course of acti on. Additional stability data may b e available which would allow continued 
use of the study drug, or study drug may need to be replaced.5.6. Route of AdministrationEIDD-2801 is administered orally.5.7. Participant Care ImplicationsParticipants who receive EIDD-2801 during this study will be mo nitored for AEs and other safety 
findings.  Virology samples will be collected and SOC for COVID- 19 will be administered. Participation 
in this study will not alter clini cal decisions w ith regards to  hospital treatment, discharge, or outpatient 
management. Participants who are admitted and e nrolled at one participating  site who are then transferred to another 
participating site, will continue to remain on study and will c ontinue to receive study drug or placebo as
initially assigned.5.8. Returns and ReconciliationsAt completion of the study, st udy drug will either be disposed of at the study site according to the study 
siteâ€™s standard operating procedure or will be returned to the sponsor with the appropriate 
documentation. The siteâ€™s method of destroying sponsor-supplied study drug must be agreed to by the 
sponsor. The site must obtain wr itten authorizatio n from the sponsor before any sponsor-supplied study 
drug is destroyed, and study drug de struction must be documente d on the appropriate form.
Protocol EIDD-2801-2004
Ridgeback Biotherapeutics LP Version: 7.0
18 May 2021
Page 39 of 64
5.9. Pharmacokinetics
Pharmacokinetic analysis will be performed in a subset of study participants and will be conducted based 
on local laboratory capacity.  The  PK secondary (plasma) and exploratory (PBMC) objectives will be 
limited to clinical sites that ar e able to participate, including but not limited to  
Blood samples will be collected for plasma isolation and PBMC preparation to characterize EIDD-2801/EIDD-1931 and EIDD-2061 PK parameters.  Previous studies d emonstrated an EIDD-1931 PK t
1/2
of 0.969 hours in healthy human subjects (EIDD-2801 Investigatorâ€™ s Brochure, V3.0, 2020).  The 
calculated t 1/2of the EIDD-2061 metabolite is 4 hours, based on ex vivo incubation studies.  Based on 
currently available PK data, additional pharmacologic analyses will be conducted in a subset of SARS-
CoV-2-infected individuals. 
Post-enrollment and initia tion of therapy, and after an overnig ht fast (i.e., no food or liquid except for 
water after midnight), PK assessment will initiate on Day 3 for pa rticipants who are still inpatients.  For 
EIDD-2801/EIDD-1931 analysis, blood will be collected on Day 3 at  pre-dose, as well as 0.5 hours,
1.5 hours, 3 hours, 6 hours, 8 hours, on Day 3 and 24 hours post-Day 3 do se on Day 4 where possible. If
a participant is scheduled to be di scharged, then PK samples shou ld be collected at all scheduled time 
points up to the time of discharge. In addition, if a participant is discharged prio r to the 24-hour PK 
sample, a 12-hour PK sample on D ay 3 should be collected, when pos sible.  
Blood sampling for PBMC isolat ion and EIDD-2061 measurements will occur at pre-dose, as well as 
0.5 hours, 1.5 hours, 3 hours, 6 hours, 8 hours, and 24 hours post-dose on Day 3 where possible, as 
described in the previous paragraph.  Time of dose will be reco rded on eCRFs.
Sparse PBMC sampling will be conducted to estimate EIDD-2061 t 1/2and AUC tau.  C maxand t maxwill be 
estimated.  PK analyses in PBMC will be conducted as an exploratory objective t o understand and 
characterize parent : metabolite (EIDD-1931:EIDD-2061) ratios at each time point, as well as persistence 
of EIDD-2061 after EIDD-1931 clearance from plasma.  
Samples may be collected within a  Â± 15 minute window (for timep oints up to 3 hours post dose), 
Â±30 minutes (for timepoints 6 -8 hours post dose); and Â± 1 hour (for timepoints 12-24 hours post dose).  
Full processing details for plasma and PBMC PK will be provided  within the study s pecific manual. 
Sample AnalysisPlasma PK analysis will be perform ed at  
. PBMC analysis will be performed under the cont rol of the  
 
The details of s ample collection and analysis wi ll be included in the Laboratory Manual 
and standard operating procedures ( SOPs). Raw data will be arch ived at the bioanalytical site.

Protocol EIDD-2801-2004
Ridgeback Biotherapeutics LP Version: 7.0
18 May 2021
Page 40 of 64
6. STATISTICAL CONSIDERATIONS
6.1. Sample Size and Power ConsiderationsWe will test the hypothesis that EIDD-2801 will result in a lar ger proportion of NP swab s from recipients 
becoming undetectable (below the LOD of the assay) for SARS-CoV -2 RNA at Day 5 of EIDD-2801 
administration compared to placebo . Participants receiving the s ame dose across the study parts will be 
pooled together in the final anal ysis.  It is expected that 14 or more participants will receive EIDD-2801 
in the higher dose groups, and at least 14 participants will re ceive placebo acro ss the study parts. The 
power calculations were based on an individual dose arm versus placebo comparison, using a Fisherâ€™s 
exact test. Based on previous data (Wolfel, Nature, 2020), if we assume that 80% of the placebo arm and 
20% of an EIDD-2801 arm are detectable at Day 5, we will have 83% power to detect a difference with 
Ä® 6.2. Statistical Analysis6.2.1. Analysis PopulationsScreened
All patients who consent to pa rticipate and who undergo screeni ng will be included in the Screened 
population.  Safety
All patients treated with at least one dose of study drug will be included in the Saf ety population. Safety 
patients are analyzed according to their actual treatment recei ved.
Intent-to-treat Set
The Intent-to-treat set (ITT) will consist of all randomized pa tients. ITT patients are analyzed according to 
their randomized treatment.Efficacy Analysis Set
The Efficacy Analysis Set (EAS) will consist of all participant s treated with at leas t one dose of study 
drug and with at least 1 post base line assessment of SARS-CoV-2 RNA in NP swabs by qPCR. Efficacy 
analysis set participants are analyzed according to their actual treatment received.Per Protocol Set 
The Per-Protocol Set (PPS) will consist of all participants in the ITT population who do not have any 
important protocol deviations l eading to exclusion from the PPS .
Protocol deviations are defined  as any change, divergence, or d eparture from the study design or 
procedures defined in the study protocol. Importa nt protocol deviations are a subset of protocol deviations 
and may significantly impact the c orrectness, accuracy, and/or reliability of the study data or that may 
significantly affect a s ubjectâ€™s rights, safety, or well-being.   
Protocol EIDD-2801-2004
Ridgeback Biotherapeutics LP Version: 7.0
18 May 2021
Page 41 of 64
Only those important protocol devi ations considered to have a m ajor effect on efficacy will lead to 
complete exclusion of the particip ants from the PPS. Details will be provided in a Statistical Analysis 
Plan (SAP).
Pharmacokinetic 
All participants treated wit h at least one dose of study drug w ith at least 1 reportabl e concentration of 
EIDD-will be included in the P harmacokinetic (PK) population.
6.2.2. Data HandlingDay 1 is defined as the day of fi rst dose of study drug. Relative days after Day 1 are calculated as 
(assessment date â€“ Day 1 date) + 1. Relative days prior to Day 1  are calculated as (assessment date â€“ Day 
1 date). The day prior to Day 1 is Day -1.All data will be analyzed usi ng nominal study visits as defined  in the Study Schedule and eCRF. No visit 
windows will be applied for summary and analysis. Unscheduled v isits will be listed but not tabulated.
Participants who received the same dose (i.e., placebo) across stu dy parts will be combined into the same 
dose group. Data from the active treatment arms may be combined for analysis, when appropriate in 
comparison with the pooled placebo group.  
6.2.3. Handling of Dropouts, Missing Data, and OutliersParticipants who prematurely dis continue from the study without receiving a single dose of study drug or 
placebo will be replaced. Particip ants who receive at least a sin gle dose of study drug who prematurely 
discontinue study drug should continue to undergo regularly sch eduled visits, including an end of study 
visit at Day 28, to evaluate c linical assessments, AEs, and SAEs for the analysis of t he primary efficacy 
endpoint, if there is no swab is av ailable for analysis then th e patientâ€™s response will be imputed to have a 
detectable level of SARS-CoV- 2 RNA by qPCR (non-response). Longitudinal analyses of secondary 
endpoints, such as the rate of decline of log
10viral RNA copies/mL for each method of sample collection, 
will use mixed effect models wh ich are robust for missing data when this is missing completely at random 
(MCAR) or missing at random (MAR). Missing safety data will gen erally not be imputed. Details and 
exceptions will be provided in the SAP. No rules for outlier det ection are planned.
6.2.4. Analysis of Primary EndpointTo address the primary endpoint, we will use a Fisherâ€™s exact t est to calculate the likelihood that a 
difference in detectable SARS-CoV-2 between a given dose of stu dy drug (EIDD-2801 400 mg up to 800 
mg) versus placebo, occurs by chance. Because the current SARS-CoV -2 RNA test is only 70% sensitive, 
we will perform 2 NP swabs at baseline and 2 NP swabs on Day 5, ea ch analyzed separately (4 total NP 
swab measurements). Thus, an undetectable result at a given tim e point will be determined when neither 
NP swab has detectable (below the LOD of the assay) viral RNA at  that time point. To graphically present 
the results, we will show individual points and smoothed curves  to fully account for individual negative 
tests that are contemporaneously observed with positive tests. 
Protocol EIDD-2801-2004
Ridgeback Biotherapeutics LP Version: 7.0
18 May 2021
Page 42 of 64
6.2.5. Analysis of Secondary Endpoints
Secondary Virologic Endpoints:
1. Time to clearance of viral RNA in NP swabs
-by qPCR 
2. The decline in viral RNA  by Day 3, Day 5, Day 8, Day 11, Day 15, Day 19, and Day 28 after 
initiation of study drug in NP swabs
-- by qPCR 
3. Rate of decline in viral RNA (change in log 10copies/mL per day) in NP swabs
-- by qPCR 
The time to clearance of viral R NA will be analyzed using the Ka plan-Meier method. T he event time of 
median, 25th, 75thpercentiles and associated 95% confidence intervals will be pro vided by dose group. 
The cumulative probability of BL OQ and the associated 95% confi dence interval for the scheduled visit 
will also be provided by dose group.
The decline in viral RNA over time will be analyzed using a mix ed effect of repeated measure model 
(MMRM). The model estimated between-group differences and assoc iated 95% confidence intervals will 
be provided by scheduled visits. The rate of decline for each d ose group will be estimated using a mixed 
effect linear model. 
Additional details will be descri bed in a SAP and finalized bef ore database lock. 
Details for the analyses of e xploratory virologic endpoints will be described in the SAP.
6.2.6. Analysis of Adverse Event Data
Analysis of AE data will primarily be descriptive based on the DAIDS table for Grading the Severity of 
Adult and Pediatric Adverse Events, July 2017, version 2.1. Adve rse events will be coded using the 
Medical Dictionary for Regulatory Activities (MedDRA). An AE is considered treatment-emergent if it 
begins or worsens in severity a fter the first dose of randomized study drug. The number and percentage of 
participants with tr eatment-emergent AEs w ill be tabulated by sys tem organ class (SOC) and preferred 
term. Additional AE summaries  will be provided by severity, dru g related AEs, AEs leading to study drug 
discontinuation, and serious AEs.6.2.7. Analysis of Other Safety and Clinical Data Other safety and clinical endpoints will be provided descriptiv ely by dose group and scheduled time of 
assessment where appropriate.  D etails will be p rovided in the SAP.
Protocol EIDD-2801-2004
Ridgeback Biotherapeutics LP Version: 7.0
18 May 2021
Page 43 of 64
6.2.8. Analysis of Pharmacokinetic Data 
Plasma EIDD-1931 PK Endpoints:
1. Maximum EIDD-1931 concentration (C max)
2. 1.5-hour EIDD-1931 concentration (C 1.5)
3. 3-hour EIDD-1931 concentration (C 3)
4. Area under the concentrati on: time curve EIDD-1931 (AUC 0-8)
5. Elimination half-life (t 1/2) EIDD-1931
PBMC EIDD-2061 PK Endpoints:
1. Maximum EIDD-2061 concentration (C max)
2. EIDD-2061 time of maximal concentration (t max)
3. Elimination half-life of EIDD-2061 (t 1/2)
4. Area under the concentrati on: time curve EIDD-2061 (AUC 0-12)
5. Parent: metabolite (Plasma EIDD-1931:PBMC EIDD-2061) concentr ation ratio at each time point
PK data will be summarized by dose group and scheduled time of assessment where app ropriate. If data 
permit, assessment of dose propor tionality will be performed and  the relationship between the exposure 
parameters and virologic endpoints will be explored. Details wi ll be described in the SAP.
Protocol EIDD-2801-2004
Ridgeback Biotherapeutics LP Version: 7.0
18 May 2021
Page 44 of 64
7. STUDY PROCEDURES
7.1. Schedule of Events
Inpatient
Study Procedures Screeninga
Day -2 to 1Day 1 Day 3 Day 4 Day 5 Day 8 Day 11 Day 15 Day 19 Day 28 (EOS) Early 
Discontin-
uation
Informed Consent X
Demo graphic data X
Inclusion/Exclusion Criteria X
Randomizationb X
Medical Histor y X
Pregnancy tes tc X XX
Serology (plasma )dXe XX
Height, wei ght, BMI X
Stud y residenc y
Visit while hospitalized for MR reviewXX X X X XXX X X
Prior/Concomitant medication 
reviewXX X X X XXX
Stud y drug vs. placebo
EIDD-2801 or PBO 
administrationfBID on 
Days 1-5BID on 
Days 1-5BID on 
Days 1-5BID on 
Days 1-5
Virolo gic endpoints
NP swab sgXeXeXe XX X X
BAL and/or sputumh XX XX X X X
Clinical endpoints
WHO Ordinal Scale 
(Appendix 1)iXiXX X X X X X X
Clinical assessment sj XX XX X X X X X
Safety and tolerabilit y
AE/SAE reportin g XX XX X X X X X
Vital signs (temperature, blood pressure, pulse, respirator
y rate)XX X X X XXX X X
Pulse oximetryk XX X X X XXX X X
Full ph ysical examination X X
Targeted physical examinationl XX XX X X X X
LaboratorymXX X X X X
Protocol EIDD-2801-2004
Ridgeback Biotherapeutics LP Version: 7.0
18 May 2021
Page 45 of 64
Inpatient
Study Procedures Screeninga
Day -2 to 1Day 1 Day 3 Day 4 Day 5 Day 8 Day 11 Day 15 Day 19 Day 28 (EOS) Early 
Discontin-
uation
12-lead ECGnX 1 posttreatment ECG to be performed, as feasiblen
Chest radio graphyoXX XX X X X X X
Pharmacokinetics
Plasm apXX
PBMC spXX
Abbreviations:  AE = adverse ev ent; BAL = bronchoalveolar lavag e; BID = twice daily; CBC = comp lete blood count; CMP = complet e metabolic 
panel; ECG = electrocardiogram; EOS = end of study; h = hours; ICU = intensive care unit; IL-6 =  interleukin 6;  
 MR = medical record; NP = nasopharyngeal; PBMC = peripheral blood mononu clear 
cell; PBO = placebo; PK = pharmacokinetic; QD = once daily; QOD  = every other day; SARS-CoV-2 = severe acute respiratory syndro me-
coronavirus-2; SOE = schedule of  events; WHO = World Health Organization. 
a. Screening and Day 1 procedures will occur on the same day whe never possible as soon as SARS-Co V-2 testing is determined to be positive.
A window of up to 6 days is allowable if the participant has not  had symptoms for more tha n 7 days prior to dosing.
b. Randomization can happen at Screening or Day 1c. For women of child-bearing pot ential only, high sensitivity s erum pregnancy tests are require d at Screening within 24 hours of the first dose 
of study drug and on Day 28.  Addi tional serum or urine pregnan cy tests may be performed, as dete rmined necessary by the investigator or 
required by local regulation, to establish the absence of pregnancy at any time during the subjec t's participation in the stud y. 
d. Serology testing will be performed on plasma for immune response on Day 1 (pre-dose), Day 5, and Day 19, and specimens will be archived 
for further cytokine testing in the future.
e. The sample should be collected pre-dose.  
f. EIDD-2801 and PBO are to be administered BID on Days 1-5. The first dose will be administered in the morning of Day 1, if po ssible. If the 
first dose is given later in the  day, the second dose may be gi ven at least 4 hours later on Day 1. If the first dose on Day 1 is given in the late 
evening, the second dose may be taken on the morning of Day 2, in which case the final dose will be taken on the morning of Da y 6.  In the 
event of missed doses, if the total number of missed doses is 4 or fewer, the number of days of study drug can be extended by no more than 1 
day (through Day 6) for the equi valent of missed doses up to 2 doses. If the participant misses more than 4 consecutive doses, or more than 5 
total doses, then the participan t will be discontinued from any further study drug administration and followed for safety for t he remainder of 
the study. 
g. One NP swab will be collected from each nostril at each time po int for a total of 2 swabs per time point.
h. BAL and/or sputum fluid may be collected when available for viral RNA testing. No study specific interventions will be initiated for 
collection of BAL fluid and/or sputum if participant has a prod uctive cough. If, during clinical care, BAL is performed and ex cess fluid is 
available, the study team will collect this fluid for testing. 
i. Note that on Day 1, the WHO or dinal scale assessment should b e performed before the first dose of EIDD-2801 is administered.  
j. Clinical assessments will be a scertained by chart extraction and will include number of day s in the hospital, maximum O
2requirements daily, 
ICU admission and number of days in the ICU, mechanical ventila tion and number of days requiring mechanical ventilation, death , and 
symptom reporting.

Protocol EIDD-2801-2004
Ridgeback Biotherapeutics LP Version: 7.0
18 May 2021
Page 46 of 64
k. Oxygen saturation is to be recorded twice daily (morning and e vening) and may be ascertained by chart extraction; if not avail able in the 
participantâ€™s chart, it should be measured by the study staff. 
l. Targeted physical examinations should be done if indicated by an AE or as needed in the jud gement of the investigator. 
m. Laboratory measurements will in clude CBC with differentials, CMP (including amylase and lipase), and urinalysis. 
n. For ECGs, a single post-dosing recording should  be collected. If the participant is discharge d from the hospital before a po st-dose ECG is 
recorded, and recording of an outpatient ECG is not feasible, then results of the last recorded ECG before hospital discharge will be entered 
into the CRF.
o. Results of all chest radiography performed as part of routine  clinical care during Study Days 1-28 should be recorded. 
p. Plasma and PBMC samples for PK  analysis will be collected from participants if they are still inpatients on Day 3.  Samples will be collected 
before the morning dose on Day 3  and at the following times aft er the Day 3 morning dose: 0.5 hours, 1.5 hours, 3 hours, 6 hour s, 8 hours, 
and 24 hours (i.e., on the morning of Day 4). If a participant is scheduled to be discharged, then  PK samples should be collected  at all 
scheduled time points up to the time of discharge; in addition,  if a participants is discharged prior to the 24-hour PK sample, a 12-hour PK 
sample should be collected, when possible.  PK measurements wil l be assessed in participants enrolled at clinical sites able t o conduct the 
collections. These sites include, but are not limited to,   Sam ples may 
be collected within a Â± 15 minute window (up to 3 hours), Â± 30 m inutes (6-8 hours), or Â± 1 hour (12-24 hours).

Protocol EIDD-2801-2004
Ridgeback Biotherapeutics LP Version: 7.0
18 May 2021
Page 47 of 64
Outpatien ta
Study Procedures Day 3 Day 5bDay 8
(Â±1 day)Day 11
(Â±1 day)Day 15
(Â±1 day)Day 28 
(EOS)
(Â±2 da ys)Early 
Discontin-
uation
Serology (plasma )c XX X
Pregnanc y testdXX
Stud y residenc y
Outpatient visit X X X X X X
Phone cal le X
Stud y drug vs. placebo
EIDD-2801 or PBO administrationf BID on Days 
1-5BID on 
Days 1-5
Virolo gic endpoints
NP swabsg,h XXXX X X
Clinical endpoints
WHO Ordinal Scale (Appendix 1 )h XXXXX X X
Safety and tolerabilit y
Concomitant medication review X X X X X X X
AE/SAE reportingh XXXXX X X
Vital signs (temperature,  blood pressure, pulse, 
respiratory rate)hXXXX X X
Pulse oximetryj XXXX X X
Targeted ph ysical examinationkXXXX X X
Laborator ylXXXX X X
Chest radio graphymXXXX X X
Abbreviations:  AE = adverse ev ent; BAL = bronchoalveolar; BID = twice daily; CBC = complete b lood count; CMP = complete metabolic panel; 
ECG = electrocardiogram; EOS = end of study; ICU = intensive ca re unit; IL-6 = interleukin 6;  
; MR = medical record; NP = nasopharyngeal; PBO = placebo; PK = pharmacokinetic; QD = once  daily; 
QOD = every other day; SOE = schedule of events; WHO = World He alth Organization. 
a. For participants who are dischar ged from the hospital after r andomization and administration of the first-dose of study drug  or PBO, this 
schedule will apply. Day number w ill be counted from enrollment.  Participants will enter the Outpatient SOE upon day of dischar ge. 
Outpatients will be seen in one  of several locations, including  but not limited to COVID-19 ambulatory pods, COVID-19 ambulato ry 
clinics and clinical research units, and home visits. In all cas es, visits will conform to infection control practices that are  established by the
institution.
b. If Day 5 falls on a Saturday , then a visit will occur on Day 4. If Day 5 falls on a Sunday, then a visit will occur on Day 6 .

Protocol EIDD-2801-2004
Ridgeback Biotherapeutics LP Version: 7.0
18 May 2021
Page 48 of 64
c. Serology testing will be performed on plasma for IL-6 levels o n Day 1 (pre-dose), Day 5 and Day 28, and specimens will be archived for 
further cytokine testing in the future.
d. Pregnancy test is required for women of childbearing potentia l only.  High sensitivity serum pregnancy tests are required on  Day 28.  
Additional serum or urine pregna ncy tests may be performed, as determined necessary by the investigator or required by local r egulation, 
to establish the absence of pregnancy at any time during the su bject's participation in the study.
e. Phone calls will be used to que ry participants about symptoms, study drug adherence, concomitan t medications and to assess WH O 
ordinal scale.
f. EIDD-2801 and PBO are to be administered BID on Days 1-5. The first dose will be administered in the morning of Day 1, if pos sible. If
the first dose is given later in the day, the second dose may b e given at least 4 hours later on Day 1. If the first dose on Day  1 is given in 
the late evening, the second dose may be taken on the morning of  Day 2, in which case the final dose will be taken on the morni ng of 
Day 6.  In addition, if a participant misses up to 2 doses during Days 1 to 5, dosing may be ext ended into Day 6. If discharge o ccurs prior 
to completion of study drug dosing (prior to Day 6), study drug  will be administered in the hos pital on the morning of dischar ge, and the 
remainder of the study drug will be dispensed for administratio n at home by the participant. Procedures will be put into place  to ensure 
study drug compliance (e.g., telephone, eCollection) and drug a ccountability will be assessed on Days 5 and 8.
g. One NP swab will be collected from each nostril at each time point for a total of 2 swabs per time point.
h. Will be obtained at least once on the indicated day AND on th e day of discharge from inpatient to outpatient, at the discret ion of the 
investigator in consultation with the sponsor.
i. Clinical assessments will be a scertained by chart extraction,  including number of days in the hospital, maximum O 2requirements daily, 
ICU admission and number of days in the ICU, mechanical ventila tion and number of days requiring mechanical ventilation, death , and 
symptom reporting.
j. If the oxygen saturation value is <92%, the measurement shoul d be repeated once within 30 minutes.
k. Targeted physical examinations should be done if indicated by  an AE or as needed in the judgement of the investigator.
l. Laboratory measurements will in clude CBC with differentials, CMP (including amylase and lipase), and urinalysis. 
m. Results of all chest radiography performed as part of routine  clinical care during Study Days 1-28 should be recorded. 
Protocol EIDD-2801-2004
Ridgeback Biotherapeutics LP Version: 7.0
18 May 2021
Page 49 of 64
8. ADVERSE EVENTS, RISKS, AND BENEFITS
8.1. Potential Benefits of treatmentBased on animal efficacy studies , it is expected that EIDD-2801  will be active against SARS-
CoV-2 infection in humans.  This st udy will examine virologic r esponses to treatment with 
EIDD-2801 and is not powered to det ect clinical outcomes.  However, clinical improvement will 
be recorded for secondary/exploratory analysis.8.2. Potential benefits of clinical monitoring Benefits of participation in thi s study include t he increased c linical monitoring of study 
participants.  Intensive virology testing will be conducted.8.3. Potential risksThe AE profile for EIDD-2801 is preliminary and derives from a Pha se 1 study that is ongoing.
Thus far, AE that were determin ed to be attributable to EIDD-2801 include insomnia, headaches, 
nausea, vomiting, abdominal pain, and loose stools ( seethe EIDD-2801 Investigatorâ€™s Brochure,
V3.0, 2020) .  
 
Gastrointestinal events and liv er enzymes will also be monitored.  
8.4. AlternativesThe alternative to participati on in this study is routine care and monitoring of COVID-19, receipt 
of a SOC treatment for SARS-CoV-2 infection if available, or par ticipation in a different clinical 
trial, if available.8.5. Definitions8.5.1. Adverse EventAdverse event is defined as any undesirable sign, symptom or med ical condition occurring after 
starting the study drug (or therapy/ intervention) even if the e vent is not considered to be related 
to the study. An undesirable medi cal condition can be symptoms (e.g., nausea, chest pain), signs 
(e.g., tachycardia, enlarged liver) or  the abnormal results of an inve stigation (e.g., laboratory 
findings, electrocardiogram). M edical conditions/diseases prese nt before starting the study 
treatment are only considered AEs i f they worsen after starting  the study treatment (any 
procedures specified in the prot ocol). Adverse events occurring before starting the study 
treatment but after signing the i nformed consent form will not be recorded. Abnormal laboratory 
values or test results constitute AEs only if they induce clinic al signs or symptoms or require 
investigation or therapy (i.e., are  considered to be clinically significant).
This study will use the descriptions and grading scales found i n the DAIDS Adverse Event 
Grading Scale for AE reporting.  

Protocol EIDD-2801-2004
Ridgeback Biotherapeutics LP Version: 7.0
18 May 2021
Page 50 of 64
8.5.2. Serious Adverse Event
An SAE is an undesirable sign, symptom or medical condition which : 
xResults in death 
xIs life threatening (defined as an event in which the participa nt was at risk of death at the 
time of the event; it does not refer to an event which hypothet ically might have caused 
death if it were more severe) 
xRequires inpatient hospitalizati on or causes prolongation of ex isting hospitaliz ation (see 
note below for exceptions)
xResults in persistent or significant disability/incapacity 
xIs a congenital anomaly/birth def ect (note: reports of congenital anomalies/birth defects 
must also be reported on the Pregnancy Supplemental Form, altho ugh participants must 
have a negative pregnancy test  prior to thera py and use at least 2 forms of non-hormonal
contraception.  All participants (men and women) must state that they will use 2 forms of 
contraception during the study and f or 4 days after completion of EIDD-2801 dosing in
female participants and for 4 da ys after completion of EIDD-2801 d osing in female 
partners of male participants.
xIs an important medical event (de fined as a medical event(s) th at may not be immediately 
life-threatening or result in death or ho spitalization but, bas ed upon appropriate medical 
and scientific judgment, may jeo pardize the participant or may r equire intervention [e.g., 
medical, surgical] to prevent  one of the other serious outcomes listed in the definition 
above.). Examples of such events include, but are not limited t o, intensive treatment in an 
emergency room or at home for a llergic bronchospasm; blood dysc rasias or convulsions 
that do not result i n hospitalization.)
Events not considered to be SAEs are  hospitalizations for the: 
xAdmissions as per prot ocol for a planned med ical/surgical procedure or to facilitate a 
procedure.
xRoutine health assessment requi ring admission for baseline/tren ding of health status (e.g., 
routine colonoscopy).
xMedical/surgical admission for pu rpose other than remedying ill  health state and was 
planned prior to entry into the study. Appropriate documentatio n is required in these 
cases.
xAdmission encountered for another life circumstance that carrie s no bearing on health 
status and requires no medical/s urgical intervention (e.g., lac k of housing, economic 
inadequacy, care-giver respite, family circumstances, administr ative).
Protocol EIDD-2801-2004
Ridgeback Biotherapeutics LP Version: 7.0
18 May 2021
Page 51 of 64
xEscalation of care that is consid ered part of the disease progr ession of COVID-19 
(including but not limited to need f or escalation in supplemental oxygen, need for 
mechanical ventilation, need for  intubation, admission to the I CU, cytokine release 
syndrome [defined by an  elevation in IL-6 and CRP levels], thro mboembolic events) will 
not be collected as SAE.
xPregnancies will be reported us ing the SAE reporting guidelines for expedited reports 
(Section 8.10.4) .
8.6. Relationship
The relationship of an AE to the  administration of the study dr ug is to be assessed by the 
investigator according to the following definitions:
xNo (unrelated, not relat ed, no relation): The time course betwe en the administration of 
study drug and the occurrence or worsening of the AE rules out a causal relationship and 
another cause (concomitant drugs, therapies, complications, etc .) is suspected.
xYes (related): The time course be tween the administration of study drug and the 
occurrence or worsening of the A E is consistent with a causal relationship and no other 
cause (concomitant drugs, thera pies, complications, etc.) can b e identified. 
The following factors should also be considered:
xThe temporal sequence from st udy drug administration - The even t should occur after the 
study drug is given. The length of time from study drug exposure to event should be 
evaluated in the clinical  context of the event.
xUnderlying, concomitant, intercu rrent diseases - Each report sh ould be evaluated in the 
context of the natural history a nd course of the disease being treated and any other 
disease the participant may have. 
xConcomitant medication - The other medications the participant is taking or the treatment 
the participant receives shoul d be examined to determine whethe r any of them might be 
recognized to cause the  event in question. 
xKnown response pattern for this  class of study drug - Clinical and/or preclinical data may 
indicate whether a particular response is likel y to be a class effect.
xExposure to physical and/or ment al stresses - The exposure to s tress might induce 
adverse changes in the recipien t and provide a logical and bett er explanation for the 
event. 
xThe pharmacology and PK of the study drug - The known pharmacol ogic properties 
(absorption, distribution, meta bolism, and excre tion) of the st udy drug should be 
considered. 
Protocol EIDD-2801-2004
Ridgeback Biotherapeutics LP Version: 7.0
18 May 2021
Page 52 of 64
8.7. Assessment of Grade/Severity
The investigator will assess gr ade for each AE and SAE reported during the study, which will be 
recorded in the CRF. The assessment will be based on the DAIDS A E Grading Table, corrected 
Version 2.1, July 2017, which is ava ilable on the DAIDS RSC webs ite at 
https://rsc.niaid.nih.gov/clinical -research-sites/daids-adverse-event-grading-tables.
Any AE that changes in grade during its course will be recorded  in the CRF at the highest level 
experience by the participant.8.8. ExpectednessUnexpected adverse event: An AE , which varies in nature, intensi ty or frequency from 
information on the investigational drug/agent provided in the I B, package insert or safety reports. 
Any AE that is not included in the informed consent is considere d â€œunexpectedâ€. A t the time of 
this protocol, no events are cons idered to be expected for safet y reporting purposes.
Expected (known) adverse event: An AE, which has been reported in the package insert. An AE
is considered â€œexpectedâ€, only if it is included in the informe d consent document as a risk.
8.9. Handling of Expedited Safety ReportsIn accordance with local regulations, the IND sponsor or designe e will notify inve stigators of all 
SAEs that are unexpected (i.e., no t previously described in the  IB), and related to EIDD-2801.
This notification will be in the f orm of an expedited safety re port (ESR) that is to be emailed to 
the investigators and the st udy coordinators. Upon receiving su ch notices, the investigator must 
review and retain the notice with  the IB and where required by local regulations, the investigator 
will submit the ESR to the appropriate IRB. The investigator an d IRB will determine if the 
informed consent requires revi sion. The investigator should als o comply with the IRB 
procedures for reporting any other safety information. 8.10. ReportingInformation about all AEs, wheth er volunteered b y the participant, discovered by investigator 
questioning, or detected through physical examination, laboratory test or other means, will be 
collected, recorded, and followed as appropriate. 
All AEs experienced by participants will be collected and repor ted from the first dose of 
EIDD-2801, throughout the study, and will only be followed for 28 days unless related to the 
investigational agent.  
Participants who have an ongoing AE related to the study procedu res and/or medication(s) may 
continue to be periodically con tacted by a member of the study staff until the event is resolved or 
determined to be irreversi ble by the investigator.
Protocol EIDD-2801-2004
Ridgeback Biotherapeutics LP Version: 7.0
18 May 2021
Page 53 of 64
8.10.1. Routine Adverse Event Reporting
If an ongoing AE changes in its intensity or in its perceived r elationship to investigational 
product, the maximum severity of the AE will be recorded. Adver se events should be followed to 
resolution or stabiliz ation or reported as SAEs if they become s erious. Follow-up is also required 
for AEs that cause interruptio n or discontinuatio n of investiga tional product, or those that are 
present at the end of study partic ipation. Participants with AE s at study completion should 
receive post-treatment f ollow-up as appropriate. 
All identified non-serious AEs mu st be recorded and described o n the appropriate Adverse Event 
Case Report Form (CRF).8.10.2. Laboratory Test Abnormalities Laboratory abnormalitie s present at the screening visit will be  recorded as pre-treatment signs 
and symptoms. After study treatme nt administration, all grade 3  and 4 clinical laboratory results 
that represent an increase in severity from baseline will be re ported as AEs. A grade 1 or 2 
clinical laboratory abnormalit y should be reported as an AE only  if it is considered clinically 
significant by the investigator.In addition, the following laboratory abnormalities should also  be captured on the AE CRF page 
as appropriate: 
xAny laboratory test re sult that is cl inically significant or me ets the definition of an SAE
xAny laboratory abnormality that required the participant to have the investigational
product discontinued or interrupted
xAny laboratory abnormality that required the participant to rec eive specific corrective
therapy
It is expected that wherever possi ble, the clinical, rather tha n the laboratory term would be used 
by the reporting investigator (e .g., anemia versus low hemoglobin value). 
8.10.3. Serious Adverse Event Reporting
All SAEs (including deaths) occurring from the first dose of th e study drug through the 28 day 
End-of-Study telephon e call will be collect ed and recorded on th e Adverse Event Case Report 
Form (CRF). The PI or clinical site personnel should notify  of all  SAEs, regardless of
relationship to the investigati onal drug, within 24 hours of clin ical site personnel becoming 
aware of the event. The PI (or designee) will provide the initial  notification by sending a
completed SAE form which must include the PIâ€™s (or designeeâ€™s) assessment of the relationship
of the event to investigationa l drug and must be signed by the PI. Follow-up information, or new
information regarding an ongoing SAE, must be provided promptly to at
or via fax.

Protocol EIDD-2801-2004
Ridgeback Biotherapeutics LP Version: 7.0
18 May 2021
Page 54 of 64
The SAE Form will collect data surrounding the e vent (e.g., the  nature of the symptom[s], time 
of onset in relation to initia tion of therapy, duration, intens ity, and whether or not therapy was 
interrupted or discontinued). The Investigatorâ€™s assessment of the probable cause of the event 
will also be included. In additi on, relevant medical history, co ncomitant medications, laboratory 
and diagnostic tests reports, and pr ocedures as well as all per tinent medical information related 
to the event will also be collected.
SAEs will be reported to each par ticipating siteâ€™s IRB per insti tutional guidelines by the PI.
After the initial SAE report, t he investigator is required to p roactively follow each participant
and provide further information reg arding the participantâ€™s cond ition.
All AE(s) and SAE(s) will be followed until one of the following  conditions is met:
xResolution
xThe condition stabilizes
xThe event is otherwise explained
xThe participant is lost to follow-up
xDeath
8.10.3.1. Expedited IND Safety Reports to the FDA
All reporting to the FDA will be completed by the IND sponsor.7 Calendar-Day Telephone or Fax Report:  
The IND sponsor is required t o notify the FDA of any fatal or li fe-threatening AE that is 
unexpected and assessed by the inve stigator to be possibly rela ted to the investigational agent.  
Such reports are to be submitted to the FDA within 7 calendar days of first learning of the event. 
Follow-up information will be submitted to the FDA as soon as relevant information is available. 
15 Calendar-Day Written Report:  
The IND sponsor is required t o notify the FDA of any SAE that is  unexpected and related to the 
investigational agent in a written IND Safety Report.  Written IND Safety Reports should include an Analysis of Simila r Events in accordance with 
regulation 21 CFR Â§ 312.32.  All safety reports previously file d with the IND concerning similar 
events should be analyzed.  The  new report should contain comme nts on the significance of the 
new event considering the previous, similar reports.  
Protocol EIDD-2801-2004
Ridgeback Biotherapeutics LP Version: 7.0
18 May 2021
Page 55 of 64
Written IND safety reports with A nalysis of Similar Events are to be submitted to the FDA 
within 15 calendar days of firs t learning of the event. Follow- up information will be submitted to 
the FDA as soon as relevant i nformation is available.
IND Annual Reports:
In accordance with the regulation 21 CFR Â§ 312.33, the IND spon sor shall within 60 days of the 
anniversary date that the IND went into effect submit a brief r eport of the AEs and progress of 
the investigation.  Ple ase refer to Code of  Federal Regulations , 21 CFR Â§ 312.33 for a list of the 
elements required for the annua l report.  All IND annual reports  will be submitted to the FDA by 
the IND sponsor.
8.10.4. Pregnancy and Exposure During BreastfeedingIf a pregnancy is reported, the investigator will record pregna ncy information on the appropriate 
form and submit it to the sponsor within 24 hours of learning of  the pregnancy in a female 
participant or female partner of  male participant (after obtaining the necessary signed informed 
consent from the female partner).
Although pregnancy and infant e xposure during br eastfeeding are  not considered AEs, any 
pregnancy or infant exposure during breastfeedin g in a particip ant (spontaneously reported to the 
investigator or their designee), including the pregnancy of a m ale participantâ€™s female partner, 
that occurs during the study are reportable to the Sponsor.All reported pregnanc ies must be followed t o the completion/termination of the pregnancy. 
Any pregnancy complication will  be reported as an AE or SAE.
The medical reason (example: mat ernal health or fetal disease) for an elective termination of a 
pregnancy will be reported as a n AE or SAE. Prenatal testing sh owing a fetus will be born with 
severe abnormalities/congenital anomalies that leads to an elec tive termination of a pregnancy 
will be reported as an SAE for the fetus.Pregnancy outcomes of ectopic pregnancy, spontaneous abortion, missed abortion, benign 
hydatidiform mole, blighted ovum, fetal death, intr auterine dea th, miscarriage, and stillbirth must 
be reported as serious events (I mportant Medical Events). If th e pregnancy continues to term, the 
outcome (health of infant ) must also be reported
Protocol EIDD-2801-2004
Ridgeback Biotherapeutics LP Version: 7.0
18 May 2021
Page 56 of 64
9. SAFETY OVERSIGHT
9.1. Monitoring Plan 
1. All AE and grade 1-3 SAE will be reviewed by the protocol tea m twice monthly, or more 
if needed. All grade 4-5 SAEs will be reviewed by the protocol team within 24-48 hours 
of being received.   
2. A safety review committee (SRC) , composed of the principal inv estigator for each study 
site and the medical monitor, will be established. The Committee will review blinded 
safety data at regular interval s. If the SRC iden tifies a potentia l safety issue, they may ask 
for additional safety analyses to further assess the issue, in co operation with the sponsor.  
Details of SRC composition, respons ibilities, and procedures will be provided in a SRC 
Charter.  
Additional details can be found in Section 9.2,in the Data and Safety Monitoring Plan for the 
study, and in the Study Unblinding Plan. 9.2. Stopping Criteria for the StudyThe study enrollment and dosing wil l be stopped, and an ad hoc review will be performed if any 
of the specific following events  occur or, if in the judgment o f the study physician, participant
safety is at risk of being compromised:
I. Unexpected death of a dosed participant.  
II. Occurrence of a life-threaten ing allergic/hypersensitivity r eaction (anaphylaxis), 
manifested by bronchospasm with or without urticaria or angioed ema requiring 
hemodynamic support with pressor medications or mechanical vent ilation.  
III. A trend of unexpected SAEs related to the study product. 
IV. Two participants with a Gra de 3 or higher lab toxicity for the same parameter associated 
with the study product. 
V. An overall pattern of symptomat ic, clinical, or laboratory ev ents that the SRC considers 
associated with study product a nd that may appea r minor in term s of individual events 
but that collectively may represe nt a serious potential concern  for safety.
VI. Any other event(s) which is considered to be a SAE in the go od clinical judgment of the 
responsible physician. This w ill be appropriately documented. 
Upon completion of this review, the SRC will determine if the s tudy enrollment or study dosing 
should be interrupted or if st udy enrollment a nd study dosing m ay continue according to the 
protocol. Should the trial not be stopped at this time point, t he final analysis would need to 
account for the number of interim analyses that were conducted. Therefore, we will use the 
Oâ€™Brien and Flemming type spendi ng function to preserve the ove rall Type 1 error. This will 
Protocol EIDD-2801-2004
Ridgeback Biotherapeutics LP Version: 7.0
18 May 2021
Page 57 of 64
allow for stopping the trial ear lier should the intervention ar m be shown to be superior at an 
interim analysis.
Interim analyses: Interim analyses are planned when  25% and 50% of the final sample size 
reach Day 14 after initiation of s tudy drug. Blinded data will be reviewed by the principal 
investigators and the sponsor.  Data to be reviewed will includ e blinded summaries of the 
primary efficacy endpoint  (achievement of und etectable viral RNA  by Day 5 in NP swabs) and 
the primary safety endpoints. F or the primary safety endpoints, the cumulative incidence of each 
type of safety endpoint will be summarized by study arm in addi tion to the risk difference and 
95% confidence interval of the ri sk difference between study ar ms. The interim analyses will be 
used to inform sponsor decisions a bout whether to continue, ame nd, or stop the study. 
Protocol EIDD-2801-2004
Ridgeback Biotherapeutics LP Version: 7.0
18 May 2021
Page 58 of 64
10. ETHICS/PROTECTION  OF HUMAN SUBJECTS
10.1. Ethical Standard
The JHU and Ridgeback Biotherap eutics, LP are committed to the integrity and quality of the 
clinical studies it coordinates and implements. JHU will ensure  that the legal and ethical 
obligations associated with the c onduct of clinical research in volving human subjects are met. 
The information provided in this section relates to all JHU sit es participating in this research 
study.As the Department of Health and H uman Services continues to strengthen procedures for human 
subjectsâ€™ protections via new regulations, JHU will review these evolving standard s in relation to 
the proposed activities and will advise the investigators on th ose that may apply.
In addition, JHU has a Federal wide Assurance (FWA) number on file with the Office for 
Human Research Protections (OHRP) . The FWA number for JHU is FWA 00005834.
This assurance commits a research facility to conduct all human  subjectsâ€™ research in accordance 
with the ethical principles in T he Belmont Report and any other  ethical standards recognized by 
OHRP. Finally, per OHRP regulatio ns, the research facility will  ensure that the mandatory 
renewal of this assurance occurs  at the times specified in the regulations.
10.2. Institutional Review Board
The JHU IRB will review this protocol and all protocol-related documents and procedures as 
required by OHRP and local require ments before participant enrollment. The JHU IRB currently 
holds and will maintain a US FWA issued by OHRP for the entirety of this study.10.3. Informed Consent ProcessThe informed consent process wi ll be initiated b efore a volunte er agrees to participate in the 
study and should continue throughout the individualâ€™s study par ticipation. The part icipant or the 
participantâ€™s legally authorized  representative will sign the i nformed consent document before 
any procedures are undertaken for the study. A copy of the signed informed consent document 
will be given to the participant f or their records. The consent will explain that participants may 
withdraw consent at any time th roughout the course of the trial . Extensive explanation and 
discussion of risks and possible benefits of this investigation  will be provided t o the participant
in understandable language. Adequa te time will be provided to e nsure that the participant has 
time to consider and discuss part icipation in the protocol. The  consent will describe in detail the 
study interventions/products and r isks/benefits associated with participation in the study. The 
rights and welfare of the participants will be protected by emp hasizing that their access to and 
the quality of medical care will  not be adversely affected if t hey decline to participate in this 
study. Participants with Low English Proficiency or who are Non-English-Speakers will be 
enrolled with the use of a certified interpreter who will also serve as a consent witness. 
Protocol EIDD-2801-2004
Ridgeback Biotherapeutics LP Version: 7.0
18 May 2021
Page 59 of 64
10.4. Participant Confidentiality
Participant confidentiality is st rictly held in trust by the par ticipating investigators and their staff. 
No information concerning the st udy or the data will be release d to any unauthorized third party 
without prior written approval of  the IND Sponsor. The results of the research study may be 
published, but participantsâ€™ names or identifiers will not be r evealed. Records will remain 
confidential. To maintain confid entiality, the PI will be respo nsible for keeping records in a 
locked area and results of tests coded to prevent association w ith participantsâ€™ names.  Data 
entered into computerized files  will be accessible only by auth orized personnel  directly involved 
with the study and will be coded.  Participantsâ€™ records will b e available to the FDA, the NIH, 
the manufacturer of the study pr oduct and their representatives , investigators at the site involved 
with the study, and the IRB.10.5. Future Use of Stored SpecimensParticipants will be asked for c onsent to use their samples for  future testing before the sample is 
obtained. The confidentiality of the participant will be maintai ned. There will be no plans to re-
contact them for consent or to in form them of results. The risk  of collection of the sample will be 
the small risk of bruising or fainting associated with phlebotomy. However, these samples will 
be taken at the same time as other protocol required samples. N o human genetic testing will be 
performed on the samples.
Samples would not be shared with i nvestigators other than inves tigators at  unless outside 
investigators had relevant assays or expertise not available to the study investigators. The 
specimens would remain linked and  at . Any use of these specimens not specified in the 
current protocol will be r eviewed by the  IRB.
10.6. Data Management and Monitoring
10.6.1. Source DocumentsThe primary source documents for  this study will be the participantsâ€™ medical records. If the 
investigators maintain separate research records, both the medi cal record and the research 
records will be considered the s ource documents for the purposes of auditing the study. The 
investigator will retain a copy of source documents. The invest igator will permit monitoring and 
auditing of these data and will allo w the IRB and regulatory authorities access to the original 
source documents. The investigator is responsible for ensuring that the data collected are 
complete, accurate, and recorded  in a timely manner. Source doc umentation (the point of initial 
recording of information) should support the data collected and  entered into the study 
database/case report form and m ust be signed and dated by the p erson recording and/or 
reviewing the data. All data submitted should be reviewed by the site investigator and signed as 
required with written or electr onic signature, as appropriate. Data entered into the study database 
will be collected dire ctly from particip ants during study visits  or will be abstracted from 
participantsâ€™ medical records. T he participantsâ€™ medical records must record their participation in 
the clinical trial and what medi cations (with doses and frequen cy) or other medical interventions 
or treatments were administere d, as well as any AEs experienced  during the trial.

Protocol EIDD-2801-2004
Ridgeback Biotherapeutics LP Version: 7.0
18 May 2021
Page 60 of 64
10.6.2. Data Management Plan
Study data will be collected at the study site(s) and entered i nto the study databa se. Data entry is 
to be completed on an ongoing basis during the study.10.6.3. Data Capture MethodsSites will collect and enter the minimum necessary study data required by the electronic Case 
Report Forms (eCRFs) into the study base, which will be contain ed on the Medidata Rave 
platform. Medidata Rave has bee n validated to comply with 21 CF R Part 11 and HIPAA. Study 
personnel designated on the Deleg ation of Authority log to ente r data will be required to 
complete training to access the database. Each study site will only have access to data collected at their site, and data  captured will be iso lated from all other study sites. All actions taken in 
relation to the database will be t racked via an audit trail. The  data system includes password 
protection and internal quality ch ecks to identify data that ap pear inconsistent , incomplete, or 
inaccurate.
10.6.4. Study Record RetentionThe site investigator is responsib le for retaining all essential  documents listed in the ICH GCP 
Guidelines. The FDA requires study records to be retained for u p to 2 years after marketing 
approval or disapproval (21 C FR 312.62), or until at least 2 ye ars have elapsed since the formal 
discontinuation of clinical devel opment of the investigational agent for a specific indication. 
These records are also to be mai ntained in compliance with IRB/ IEC, state, and federal medical 
records retention requirements, w hichever is longest. All store d records are to be kept 
confidential to the extent provided by federal, state, and loca l law. It is the site investigatorâ€™s 
responsibility to retain copies of source documents.No study document should be destro yed without prior approval fr om the Principal Investigator. 
Should the investigator wish to a ssign the study records to another party and/or move them to 
another location, the site invest igator must provide written no tification of such intent to sponsor 
with the name of the person who will accept responsibility for t he transferred records and/or their 
new location. The sponsor must be  notified in writing and writt en permission must be received 
by the site prior to destruction o r relocation of research reco rds.
Protocol EIDD-2801-2004
Ridgeback Biotherapeutics LP Version: 7.0
18 May 2021
Page 61 of 64
11. REFERENCES
Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, S mith EC, Case JB, Feng 
JY, Jordan R, Ray AS, Cihlar T, Siegel D, Mackman RL, Clarke MO, Baric RS, Denison MR.  
Coronavirus Susceptibility to the  Antiviral Remdesivir (GS-5734) Is Mediated by the Viral 
Polymerase and the Proofreadi ng Exoribonuclease. mBio. 2018 Mar 6;9(2). pii: e00221-18. doi: 
10.1128/mBio.00221-18.
Agostini ML, Pruijssers AJ, Cha ppell JD, Gribble J, Lu X, Andre s EL, Bluemling GR, 
Lockwood MA, Sheahan TP, Sims AC, Natchus MG, Saindane M, Kolykhalov AA, Painter GR, 
Baric RS, Denison MR. Small-0ROHFXOH$QWLYLUDOÈ•-d-N 4-Hydroxycytidine Inhibits a Proofreading-Intact C oronavirus with a High Genetic Barrier to Resistance. J Virol. 2019 Nov 
26;93(24). pii: e01348-19. doi: 10.1128/JVI.01348-19. PMID: 315 78288.
Benson LS, Madden T, Tarleton J, Mi cks EA. Society of Family Planning interim clinical 
recommendations: contraceptive provision when healthcare access  is restricted due to pandemic 
response. Society of Famil y Planning. 28 May 2020. https://doi. org/10.46621/UYGR2287 
Painter GR, Bowen RA, Bluemli ng GR, DeBergh J, Edpuganti V, Gru ddanti PR, et al. The 
prophylactic and therapeutic activ ity of a broadly active ribonucleoside analog in a murine model 
of intranasal venezuelan equine  encephalitis virus infection. A ntiviral Res [Internet]. 
2019;171(September):104597. Availab le from: https://doi.org/10. 1016/j.antiviral.2019.104597
Sheahan TP, Sims AC, Zhou S, Graham RL, Pruijssers AJ, Agostini  ML, Leist SR, SchÃ¤fer A, 
Dinnon KH 3rd, Stevens LJ, Chappell JD, Lu X, Hughes TM, George  AS, Hill CS, Montgomery 
SA, Brown AJ, Bluemling GR, Nat chus MG, Saindane M, Kolykhalov AA, Painter G, Harcourt 
J, Tamin A, Thornburg NJ, Swanstr om R, Denison MR, Baric RS. An orally bioavailable broad-
spectrum antiviral inhibits SAR S-CoV-2 in human airway epithelial cell cultures and multiple 
coronaviruses in mice. Sci Transl Med. 2020 Apr 6. pii: eabb588 3. doi: 
10.1126/scitranslmed.abb5883. PMID: 32253226. 
Spratt DI, Buchsbaum RJ. COVID- 19 and Hypercoagulability: Poten tial Impact on Management 
with Oral Contraceptives, Estr ogen Therapy and Pregnancy [published online ahead of print, 
2020 Jul 29]. Endocrinology. 2020;bqaa121. doi:10.1210/endocr/b qaa121
WÃ¶lfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, MÃ¼ller MA, Niemeyer D, Jones 
TC, Vollmar P, Rothe C, Hoelsch er M, Bleicker T, BrÃ¼nink S, Sch neider J, Ehmann R, 
Zwirglmaier K, Drosten C, Wendtne r C. Virological Assessment of Hospitalized Patients With 
COVID-2019. Nature. 2020 A pr 1. doi: 10.1038/s41586-020-2196-x. 3 2235945
Yoon JJ, Toots M, Lee S, Lee ME, L udeke B, Luczo JM, et al. Ora lly efficacious broad-
spectrum ribonucleoside analog inh ibitor of influenza and respi ratory syncytia l viruses. 
Antimicrob Agents Chemother. 2018;62(8):1â€“18. 
Protocol EIDD-2801-2004
Ridgeback Biotherapeutics LP Version: 7.0
18 May 2021
Page 62 of 64
Appendix 1. World Health Organization Ordinal Scale for Clinical  Improvement of 
COVID-19 Disease

Protocol EIDD-2801-2004
Ridgeback Biotherapeutics LP Version: 7.0
18 May 2021
Page 63 of 64
Appendix 2. Contraceptive Guidance
Definition of Women of Chil dbearing Potential (WOCBP)
A woman is considered fertile  following menarche and until becoming postmenopausal unless 
permanently sterile (see below):
If fertility is unclear  (eg, amenorrhea in adolescents or athle tes) and a menstrual cycle cannot be 
confirmed before first dose of s tudy intervention, additional e valuation should be considered.
Women in the following categor ies are not considered WOCBP:
xPremenarchal
xPremenopausal female with 1 of the following:
oDocumented hysterectomy
oDocumented bilateral salpingectomy
oDocumented bilateral oophorectomy
For individuals with permanent  infertility due to an alternate medical cause other than the 
above (eg, Mullerian agenesis, androgen insensitivity), investi gator discretion should be 
applied to deter mining study entry.
Note: Documentation can come fro m the site personnelâ€™s review o f the participantâ€™s 
medical records, medical exami nation, or medical  history interv iew.
xPostmenopausal femaleA postmenopausal state is defi ned as no menses for 12 months wi thout an alternative 
medical cause.
oA high follicle stimulating horm one (FSH) level in the postmeno pausal range may 
be used to confirm a postmenopaus al state in women not using ho rmonal 
contraception or hormone replacement therapy (HRT).  However, i n the absence 
of 12 months of amenorrhea, confir mation with two FSH measurements in the
postmenopausal range is required.
Females on HRT and whose menopausal status is in doubt will be required to use one of 
the nonhormonal highly effective contraception methods if they wish to continue their 
HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of 
postmenopausal status bef ore study enrollment.
Protocol EIDD-2801-2004
Ridgeback Biotherapeutics LP Version: 7.0
18 May 2021
Page 64 of 64
Contraception Requirements
CONTRACEPTIVES ALLOWED DURING THE STUDY INCLUDEa:
Highly Effective Methods That  Have Low User Dependency 
Failure rate o f <1% per year when used consistentl y and correctl y.
xProgesterone-only subder mal contraceptive implantb
xIntrauterine hormone-releasing system (IUS)c
xNon-hormonal intrauterine device (IUD)
xBilateral tubal occlusion
xAzoospermic partner (vasectomized  or secondary to a medical cau se)
This is a highly effective contr aceptive method provided that t he partner is the sole male sexual partner of the 
WOCBP and the absence of sperm has been confirmed. If not, an a dditional highly effective method of 
contraception should be used. Spermatogenesis cycle is approxim ately 90 days.
Note: documentation of azoospermia for a male participant can c ome from the site personnelâ€™s review of the 
participantâ€™s medical records, medical examination, or medical histor y interview.
Sexual Abstinence
Sexual abstinence is considered a  highly effective method only if defined as refraining from heterosexual 
intercourse during the entire per iod of risk associated with th e study intervention. The reliability of sexual 
abstinence needs to be evaluated in relation to the duration of the study and the preferre d and lifestyle of the 
participant.
Highly Effective Contraceptive Methods That Are User Dependentd(must be used in combination with a 
barrier method)Combined (estrogen- and progestogen-containing ) hormonal contra ception 
Oral
Intravaginal
Transdermal
Injectable
Progestogen-only hormone contraception
b
Oral
Injectable
Barrier methods to be used with hormonal contraceptives above ( male condoms are preferred method)
xMale or female condom with or without spermicide
xCervical cap, diaphragm, or sponge with spermicide
xA combination of male condom wit h either cervical cap, diaphragm, or sponge with spermicide (double
barrier methods)
Footnotes: 
a) Contraceptive use by men or women should be consistent with local regulations regarding  the use of contraceptive 
methods for participants of clinical studies.
b) If locally required, in accord ance with CTFG guidelines, acce ptable contraceptive implants are limited to those which 
inhibit ovulation.
c) IUS is a proges tin-releasing IUD
d) Failure rate of <1% per year w hen used consistently and correctly (and not in combination with barrier method). Typical 
use failure rates are higher th an perfect-use failure rates (i. e., when used consis tently and correctly).
Note: The following are not acceptable methods of contraception  alone or in combination:
Periodic abstinence (calendar, s ymptothermal, post-ovulation me thods), withdrawal (coitus in terruptus), spermicides 
only, and lactationa l amenorrhea method.
Male and female condom s hould not be used to gether (due to risk of failure with friction ).